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Evaluation of the anticancer potential of new nitrogen heterocycles in human colon cancer 
Abstract 
 
 
 
 Colorectal cancer (CRC) is one of the most common types of cancer, being its 
incidence higher in developed countries, where diets rich in fats and sedentary life styles are 
usual. The inexistence of a cure in addition with tumor resistance to the actually used drugs 
makes imperative the search for new and effective solutions. To worsen the actual 
treatment scenario is the fact that patients do not respond equally to the administered 
drugs (for ex. Fluorouracil-5FU) due to the tumors’ different genetic profiles. This ineffective 
treatment in many patients leads to thousands of annual casualties. 
 Previously, two compounds belonging to a family of nitrogen heterocycles were 
identified as active in HCT116(p53-wt) cells of colon cancer. New compounds derived from 
these hits were synthesized for this project with the aim of potentiate their anticarcinogenic 
potential. To do so, different R and R1 groups were tested and both seem to interfere in the 
activity of the compounds. From these new compounds, 2 were identified as extremely 
potent and promising (10 and 24) in the same cell line but also in the isogenic line 
HCT116(p53-null) and CO115, with IC50s between 0.6μM and 1.55 μM, in comparison with 
the reference compound 5FU, whose IC50s are between 15 μM and 252 μM. With this 
analysis it was also possible to discover that the high activity of the compounds is 
independent of the p53 status, what presents and advantage relatively to 5FU that it Is not 
active in the absence of p53. In addition it was discovered that compound 24 is active in cells 
with both KRas and BRaf activating mutations. Their effect was assessed in cellular processes 
like apoptosis and cell cycle, where it was verified a low induction of apoptosis and 
accentuated arrest of the cell cycle in the S and G2 phases. An initial study about the effect of 
the compounds in various molecular markers related with the cell cycle and apoptosis was 
also performed, being the most visible alteration the expression of p53 and cdc25c, proteins 
involved in the cell cycle. In conclusion, with this project were identified 2 extremely potent 
compounds in different CRC genetic profiles, what confers a massive advantage relatively to 
the approved drug 5FU. 
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Avaliação do potencial anticarcinogénico de novos heterociclos de nitrogénio no cancro do 
cólon humano. 
Resumo 
 
 O cancro colorectal (CRC) é um dos tipos de cancro mais comuns, sendo a sua 
incidência maior em países desenvolvidos, onde maus hábitos alimentares e sedentarismo 
são usuais. A inexistência de uma cura juntamente com a resistência dos tumores às drogas 
actuais torna imperativa a procura por novas e eficazes soluções. A piorar o cenário de 
tratamento actual está o facto de os pacientes não responderem de igual forma às drogas 
administradas (ex. fluorouracil-5FU) devido aos diferentes perfis genéticos dos tumores. Este 
tratamento ineficaz de muitos pacientes leva à vitimização de milhares de pessoas por ano. 
 Anteriormente, dois compostos pertencentes a uma família de heterociclos de 
nitrogénio foram identificados como activos em células HCT116(p53-wt) de cancro do cólon. 
Novos compostos derivados destes hits foram sintetizados com o objectivo de potenciar a 
sua acção anticancerígena. Para tal, diferentes grupos R e R1 foram testados e ambos 
parecem interferir na actividade dos compostos. Destes novos compostos, 2 foram 
identificados como extremamente potentes e promissores (10 e 24) na mesma linha celular 
e também na linha isogénica HCT116(p53-null) e CO115, com IC50s entre 0,6μM e 1,55 μM, 
em comparação com o composto de referência 5FU cujos IC50s estão entre 15 μM e 252 μM. 
Com esta análise foi também possível descobrir que a alta actividade dos compostos é 
independente do status de p53, o que é uma vantagem em relação ao 5FU que não tem 
actividade na ausência de p53. Também se descobriu que o composto 24 é activo em células 
com Kras activamente mutado, assim como com BRaf. O efeito destes compostos foi 
avaliado em processos celulares como a apoptose e o ciclo celular, onde se verificou uma 
indução baixa de apoptose e uma acentuada alteração do ciclo celular com paragem do ciclo 
nas fases S e G2. Um estudo inicial sobre o efeito dos compostos em diversos marcadores 
proteicos relacionados com o ciclo celular e apoptose foi também realizado, sendo que a 
alteração mais visível foi a expressão de p53 e Cdc25c, proteínas envolvidas no ciclo celular. 
Em conclusão, com este trabalho foram identificados 2 compostos extremamente potentes 
em diferentes perfis genéticos de CRC, o que confere uma enorme vantagem relativamente 
à droga aprovada 5FU. 
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1. Cancer 
 
 Tissue homeostasis relies on the delicate balance between cell survival and death 
mechanisms, which ultimately determine life itself. If this balance is disturbed by some kind 
of unwanted modification in these mechanisms, homeostasis is lost. At the cellular level, loss 
of homeostasis can lead to abnormal cell growth and proliferation, a disease known as 
cancer. One of the main causes of death worldwide5, cancer is the result of the accumulation 
of several mutations, which in turn generate damages and errors that the cell is unable to 
correct. Because of these damages, cancer cells can grow and multiply without any control. 
 Over the past decades, cancer research has brought to light a small group of 
biochemical, molecular and cellular traits acquired by the majority of human cancers. 
Tumorigenesis is a multistep process responsible for the transformation of normal cells into 
malignant ones and, in this process, some of these steps were identified in all tumors. It is 
widely accepted that tumor formation is the result of six main alterations on cell physiology, 
namely: self-sufficiency on growth signals, insensitivity to antigrowth signals, evasion of 
programmed cell death (apoptosis), infinite replicative potential, tissue invasion and 
metastases and angiogenesis6 (Figure 1). Mitogenic growth signals bind to normal cells 
through specific transmembrane receptors, activating their proliferative state. Unlike cancer 
cells, in the absence of these exogenous signals normal cells are not able to grow6. Many of 
the mutated oncogenes of tumor cells mimic the effect of these growth signals, making cells 
independent to generate their own signals and less dependent on external stimulation. This 
way, the heterotypical signaling process, where one cell stimulates another, is stagnated and 
a autocrine stimulation system is established, breaking the homeostatic mechanism that sets 
the appropriate behavior of cells. One example of growth independency is the 
overexpression of growth factors (GF) receptors, found in many types of cancers, that makes 
cells hypersensitive to regular levels of GF that normally would not trigger proliferation6. 
Cells may also receive antiproliferative signals that help maintain organism homeostasis. 
These anti-growth signals can either be soluble growth inhibitors or immobilized inhibitors6, 
which can stop proliferation by two ways. They can push cells out of proliferation into a 
static state (G0) or induce cells to leave their proliferative potential definitively, entering a 
post-mitotic state6. These effects of the anti-growth signals are related with the arrest of cell 
cycle, which is going to be described in more detail in subsequent sections. The majority of 
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antiproliferative signals are regulated by the retinoblastoma protein (pRb), that when 
hypophosphorylated blocks proliferation. The third hallmark of cancer is the ability of cancer 
cells to evade programmed cell death, known as apoptosis. Once this mechanism is triggered 
by some physiological signal, a precise cascade of steps takes place6, normally in response to 
mitochondria. Found in all types of cancer, the most common strategy to escape apoptosis is 
the loss, by mutation, of the proapoptotic regulator P53 gene. This results in inactivation of 
the p53 protein, a feature common to more than 50% of human cancers6. Another strategy 
is to enhance the activity of the PI3 kinase-Akt/PKB pathway that transmits antiapoptotic 
survival signals, decreasing this way 
apoptosis. These previous three hallmarks 
– sell-sufficiency of growth signals, 
insensitivity to antiproliferative signals and 
evasion of apoptosis – brings us to the 
next common cellular trait, which is 
unlimited replicative potential. Normal 
cells die after a certain number of 
divisions, unlike cancer cells that do not 
seem to have this control and grow 
indefinitely, gaining immortality. 
Immortality is also promoted by the 
upregulation of telomerase, the enzyme responsible for maintenance of telomeres6, whose 
function is to regulate structural stability of the chromosomes. Because cancer cells grow at 
a fast pace, they have higher demands of oxygen and nutrients, which are matched with the 
formation of new vessels. Angiogenesis is the expansion of blood vessels to supply the 
cancer cells, what helps cancer cells grow and spread through the bloodstream6. 
 Recently, a new vision of the process of tumor development has been established. In 
it, tumors were analyzed as a whole, taking into account their microenvironment, and not 
only the cancer cells individually1. Classic cancer hallmarks are supported by two enabling 
characteristics, genome instability and mutations and tumor-promoting inflammations, that 
confer an advantage in the development of cancer cells. With this new view, two emerging 
hallmarks were born, namely the reprogramming of energy metabolism and evasion of 
immune destruction1 (Figure 1). 
Figure 1 – Hallmarks of Cancer. Image extracted from: 
“Hallmarks of Cancer: next generation”
1
. 
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 The consequence of the abnormal and unregulated proliferation of cancer cells is the 
formation of a mass, designated by tumor7. The distinction between a malignant and benign 
tumor resides on the fact that a benign tumor is confined. A tumor is classified as benign if 
cells tend to grow slowly and are confined to their original location. On the contrary, in 
malignant tumors, cancerous cells grow rapidly and gain the ability to invade the 
surrounding tissues, destroying and replacing them7. Only these tumors are considered 
cancers. Once malignant cells invade the lymphatic or/and circulatory systems, they can 
travel through the organism and invade other organs, where they can lodge, grow and 
multiply. The result of this process of invasion is the creation of new tumors – metastasis. Of 
all the cells present in the primary tumors only 0.01% are able to invade tissues and survive 
in the bloodstream, however metastases are a life threatening and recurrent diagnosis in 
cancer patients8. 
 Cancers are classified according to the kind of tissue from which they originate or the 
location in the body where they first developed. Carcinomas make for 90% of all human 
cancers and arise from epithelial tissue7. Other less frequent classes of cancers are 
sarcomas, derived from connective tissues like bone, cartilage and fat, lymphomas, 
originated in the hematopoietic cells that abandon the bone marrow and mature on lymph 
nodes and leukemia known as blood cancer, that arises in the bone marrow, preventing it 
from producing platelet, white and red blood cells7. 
 
1.1.  Eukaryotic Cell Cycle 
 
 The development of organisms and life itself depends on the ability of cells to create 
exact copies of themselves, in a process designated by cell cycle. All cells derive from pre-
existing cells through a series of events that lead to cell division and duplication. This highly 
regulated process originates two genetically similar cells, assuming that everything goes 
according to plan. Taken into account that the human body is constituted by about 1014 
cells,7 all derived from just one, it is fundamental that cell cycle occurs without errors in a 
well regulated manner. Cellular division serves then to maintain homeostasis in tissues, 
replacing dying cells and creating new ones when needed. Any errors in division may lead to 
mutations in the genome or aneuploidy. 
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1.1.1. Phases of the cell cycle 
 Eukaryotic cell cycle is comprised of 4 phases, arranged into interphase and 
mitosis/cytokinesis. In interphase, cells prepare for division by growing, duplicating their 
DNA and accumulating nutrients and in mitosis, they split into 2 similar cells. Interphase 
encompasses three phases – G1, S, G2 phase – and mitosis is the last one7 (Figure 2). These 4 
phases vary in length, depending on the type of cell cycle and the signals that influence it2. In 
a human cell with a normal 24hours proliferation cycle, interphase occupies the majority of 
the cycle, circa 95%, leaving about 1 hour for mitosis and cytokinesis7. In interphase, 
duration values for G1, S and G2 phase are 11h, 8h and 4 hours, respectively. 
 Gap 1 phase - G1 phase - is the first of the cell cycle and functions as a resting state 
where the cell grows and prepares for chromosomal replication, which takes place in the 
next phase2. Millions of proteins and later on enzymes, required for DNA replication, are 
formed here. Located between mitosis and DNA replication, cells in this phase are 
metabolically active and grow but no DNA is replicated7.  
 Synthesis of DNA is performed in the S phase, between G1 and G2 phases2. This 
phase starts when DNA replication begins and, at the end, DNA doubles in quantity. This 
process is completed in the minimum time possible, so that DNA base pairs are not exposed 
to external factors9 (for example mutagens like radiation, DNA reactive chemicals, virus DNA, 
base analogs and intercalating agents10) too long. 
 In the gap 2 phase – G2 phase – cellular growth continues and cells get ready for 
mitosis2. Proteins required for preparation of mitosis are now synthesized7. 
 The last phase, mitosis – M – consists in the nuclear and cell division2. Chromosomes 
and all cellular organelles are divided equally between the two daughter cells. Mitosis is 
itself constituted by several phases distinguished by the organization of the cellular 
constituents. They are prophase, metaphase, anaphase and telophase. In the end of mitosis 
cytokinesis happens2. This is not a part of mitosis but directly follows it, being responsible for 
the total separation of the cellular membrane and creation of the two new cells. Cells on 
mitosis are distinguishable by microscopy from cells on interphase7. 
 When a new cell is originated, after passing through mitosis, it can either re-enter G1 
phase, giving rise to new cells, or stop growth for an undefined period of time, a condition 
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known as G0 phase
2. Cells stay in this quiescent state until new growth stimulatory signals 
emerge. An example are skin fibroblasts that will stay ”frozen” in G0 phase until extracellular 
stimulation7. Without growth factors (eg. EGF, IGF) or nutrients, cells stop dividing and arrest 
in G0
2.  
 After fertilization, embryonic cells present smaller cycles, which results in rapid rates 
of multiplication. These initial cycles do not show gap phases, only mitosis and S phase7, 
what implicates that cells doo not grow and cell division times are rather diminished. As cells 
proliferate and the organism reaches adulthood, cycles become progressively longer. Adult 
cells end up by stopping their proliferation, some even permanently like nerve cells, 
resuming it only when necessary7. 
 Even when no errors occur during eukaryotic cell cycle, ploidy varies among its 
phases7. In G1 phase cells have their characteristic DNA content, in other words, they are 
diploid (2n). When they transition to S phase, cells change from 2n to 4n and, in the G2 
phase, then remain tetraploid7. This condition is only altered when cells divide through 
cytokinesis , returning to their natural diploid state. To ensure the correct completion of this 
cycle, an extensive mechanism of regulation is activated within cells. 
 
1.1.2. Checkpoints 
 Like all mechanisms, cell cycle needs to be supervised and controlled to ensure a 
correct functioning. If this happens to fail, daughter cells will become unfaithful copies of 
their parents7 and the principle of cellular division will be lost. In order to control the quality 
of the cycle, a series of rigorous steps, called checkpoints, exist along the cell cycle with the 
aim of verifying whether a previous event occurred correctly before starting a new one2. In 
the chance these checkpoints fail to act, genetic instability will be promoted and cells with 
damaged DNA or incorrectly partitioned chromosomes will be allowed to divide2. The result 
is propagation of cells potentially carcinogenic. 
 Cell cycle begins when the balance between growth-promoting and inhibitor factors 
is disturbed. The point at which stimulatory signals are favored and cells enter division is 
called restriction point2. Retinoblastoma protein (pRb) (result of the expression of the 
suppressor gene RB) controls this point by deciding whether the cell will pass to S phase or 
remain on G1. This protein has an inhibitory effect on the cycle progression when bound to 
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the transcription factor E2F2. After stimulation, during early G1, RB protein is 
phosphorylated and E2F factor is released, which will activate S phase genes, preparing the 
next phase2. Once cells pass this restriction point, cell cycle will continue even if growth-
stimulatory factors cease2. 
 Two major checkpoints regulate cell cycle – the G1/S and G2/M checkpoints. Right 
after cells commit to cell cycle, they are subjected to the control of the first checkpoint. In 
this, the cell ascertains mutations in DNA, arresting the cycle until DNA is repaired or the cell 
is eliminated by apoptosis2. p53 tumor suppressor is an important protein in this checkpoint. 
DNA damage activates reparation in this G1/S checkpoint. Here cells are arrested before 
entering the S phase and replication of DNA errors are avoided. 
 p53 is also important in the G2/M transition. G2/M checkpoint stops cells from 
entering mitosis if DNA’s replication is not completed, preventing cell division7. Cells remain 
arrested in the G2 checkpoint until the complete genome is replicated. In addition to correct 
DNA replication, this checkpoint also examines the existence of damages in DNA2. 
 The last checkpoint – spindle checkpoint – is situated inside mitosis. It function is to 
stop the progression of mitosis and prevent anaphase from happening in case something is 
wrong with the cell’s organization prior to division2. Incorrect assembly of the spindle or 
disordered chromosomal orientation will arrest cells in mitosis, ensuring that chromosomes 
separate correctly between the daughter cells7. 
 In the S phase, the integrity of the DNA and possible damages are also assessed. In 
this quality point, replication errors like insertion of incorrect bases or replication of wrong 
segments is evaluated7. Existence of errors, like stalled replication machinery or damages 
resulting from prolonged inability to synthesize DNA, activates the control process of this 
phase, what results in a arrest of mitosis that can be either dependent or independent of 
p5311. 
 Cell arrest in G1 and G2 phases is mediated by two DNA damage related protein 
kinases – ATM and ATR7. These kinases recognize damaged or incorrectly replicated DNA and 
are activated in response to these damages. Their signaling leads to cycle arrest and 
activation of DNA repair systems. In cases where DNA repair is impossible, programmed cell 
death is activated7. Mutations on ATM gene, responsible for ataxia telangiectasia disease, 
are often found in cancer. 
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1.1.3. Cell Cycle Regulation 
 Cell Cycle is an intricate and delicate 
process that requires the activity of several 
molecules to control and coordinate the different 
phases. Some stimulate the progression of the 
cycle and others inhibit it, altering the biological 
functions of regulatory proteins through 
phosphorylation. These important regulatory 
proteins are divided into three groups: cyclins, 
cyclin dependent kinases (CDKs) and cyclin 
dependent kinases inhibitors (CKIs), that have the 
purpose of maintaining the cycle’s delicate balance. 
 There are four types of cyclins, defined by the stage of the cell cycle in which they 
operate. All cyclins bind to cyclin dependent kinases (CDKs), other key class of cell cycle 
regulatory molecules, forming an active holoenzyme complex, as represented in Figure 2. 
CDKs are serine/threonine protein kinases that require binding to cyclins, the regulatory 
subunits2. Their activity is regulated by: association with cyclins; activating phosphorylation 
of threonine near position 160; inhibitory phosphorylation of threonine 14 and tyrosine 15, 
and association with CDK inhibitors (CKI’s)7. Normally, levels of CDKs remain stable during 
the cell cycle, whereas levels of cyclins increase and decrease through the different phases, 
with the exclusion of cyclin D2. Variation of cyclins levels respond to the rate of synthesis and 
degradation by the ubiquin-protreasome pathway2. 
 
 Starting at G1, represented in Figure 3, cyclins of this phase – cyclins D (1, 2 and 3) - 
promote the passage through the restriction point7 and, consequently, the initiation of the 
cycle. Hereafter, cyclins of the G1/S transition – cyclins E (E1 and E2) - are activated in late 
G1
7, leading the cell to commit with DNA replication and passage to S phase2. Once in S 
phase, the connection of cyclins A and CDKs is mandatory for the initiation of DNA 
replication. The last existing class of cyclins are in G2/M phase, cyclins B, that promote 
mitosis2. 
 
Figure 2 – Cell Cycle. The cell cycle is tightly 
regulated by CDK/cyclin complexes. 
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Figure 3 – G1/S checkpoint. Regulation of the transition from the G1 to S phase by several proteins. Adapted from “The 
Molecular Biology of Cancer”
2
. 
 
 Cell cycle initiation in G1 phase and passage to S phase are controlled by kinases 
CDK4/6-cyclin D and CDK2-cyclin E, but also by the complex RB-E2F2 (Figure 3). As described 
previously, RB protein controls the restriction point, arresting the cycle when bound to E2F 
transcription factor (RB-HDAC-E2F). RB phosphorylation by CDK4/6-cyclin D and CDK2-cyclin 
E will remove RB from the complex and, as a consequence, E2F will be released2, allowing 
the transcription of S phase genes, whose function is to encode proteins that enhance the 
transition between G1-S and prepare DNA replication. Cells can arrest at G1 due to the 
degradation of Cdc25A phosphatase. ATM pathway causes the phosphorylation of this 
enzyme by Chk2, what consequently leads the maintenance of the complex Cdk2/cyclin E in 
an inactive state12. G1 phase checkpoint is controlled by several stimuli, namely, TGF-β; DNA 
damage; contact inhibition; replicative senescence; oncogenic stress; and growth factors 
removal2. The first five act via the induction of the families of CKIs INK4 and KIP/CIP. One of 
the key players of this checkpoint is p53 protein. It indirectly senses DNA damage and 
decides if the cell will arrest the cycle in G1 until damage is repaired or trigger apoptosis in 
case repair is impossible. 
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 Regulation of DNA synthesis in S phase is made with the assistance of complexes 
CDK2-cyclin E/A. To start DNA replication, three elements are required: the activation of 
replication origins, activation of DNA unwinding functions and of polymerases2. Replication 
origins are prereplication complexes located at chromosomes whereas DNA helicases are 
responsible for the unwinding of DNA through the opening of the DNA helix. Activation of 
these three elements is regulated by CDK activity levels2. When CDK activity is low, 
replication origins are formed and when CDK activity levels are high, DNA polymerases and 
helicases are recruited, leading to the beginning of DNA replication. High CDK activity 
prevents the formation of more prereplication complexes, remaining high until mitosis is 
complete, moment after which activity lowers again. In addition, the transition from low to 
high levels of CDK activity are crucial for correct DNA replication2. Damages caused during 
DNA replication by, for example, ionizing radiation activate the ATM/ATR pathway and their 
signals are integrated by Cdc25A, causing a rapid cell arrest12. 
 During S phase, only one copy of DNA (4n) is made by each cycle. Like the rest of the 
process, this too has to be controlled so aneuploidy is prevented. With that purpose, 
molecular mechanisms of control exist to avoid the re-initiation of DNA replication until the 
cycle is completed. This mechanism involves mini-chromosome maintenance (MCM) helicase 
proteins in G1 phase that bind to replication origins together with ORC proteins, forming the 
origin recognition complex - ORC7. This complex is then considered licensed for replication13. 
MCM proteins only bind to DNA in G1 phase and, as soon as replication begins, MCM 
proteins leave the origin and initiation stops. These do not bind DNA in any other phases of 
the cycle as a consequence of regulatory protein kinases’ activity7. Variations of CDKs activity 
in cell cycle dictate the distinction between the licensed state of replication origins in G1-
phase and the unlicensed state in the rest of the cycle. Licensing is only allowed when CDK 
activity decreases at the end of mitosis, relieving its restriction and allowing the beginning of 
a new cycle13. As cells transit from G1 to S phase, activity of CDK increases what triggers 
initiation and prevents the formation of more complexes13, as mentioned previously. 
 
 G2/M checkpoint, whose key regulator is CDK1/cyclin B, prevents cells from entering 
mitosis in case the genome is damaged (Figure 4). 
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Figure 4 – G2/M checkpoint. Regulation of the G2/M transition by several proteins. Adapted from “The Molecular Biology of 
Cancer”. 
 
 Because of the effect of Wee1 and MYT1 kinases on tyrosine 15 and threonine 14, 
CDK1 (also known as Cdc211) remains inactivated during G2 phase and will only be activated 
near the end7. Due to the phosphorylating action of the polo-kinase PLK1, CDC25c is 
activated. This phosphatase activates CDK1 through the dephosphorylation of threonine-14 
and tyrosine-15 residues12. The now active complex CDK1/cyclin B will create a positive 
feedback with the continuous phosphorylation of Cdc25c, which will amplify the signal and 
push cells towards mitosis11. DNA damage can arrest progression of this transition, 
independently of p53, through the activation of ATM/ATR kinases. This activation starts two 
parallel cascades, schematized in Figure 4, that will  ultimately inhibit CDK1-cyclin B activity2. 
In the first cascade, which detects less profound damages, CHK activated kinases 
phosphorylate and, consequently, sequesters CDC25 in the cytoplasm where it cannot 
function11. This results in the inactivation of the CDK1-cyclin B complex. The other cascade, 
which detects major damages like double-stranded breaks (DSBs), counts with regulation by 
p53 protein. After DNA damage, p53 is phosphorylated, dissociating from the complex p53-
MDM22. This results in fully functional p53 that will bind to DNA. Genes activated by p53 will 
encode the proteins 14-3-3, GADD45 and p21CIP1. These will bind to CDK1, promoting nuclear 
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export, complex dissociation and inhibition, respectively2. Relatively to Gadd45 protein, its 
dependency on p53 in order to cause G2 arrest was identified, although it is not clear why
11. 
The effect of 14-3-3 and p21 proteins on the G2 arrest was also analyzed in HCT116 colon cell 
line, leading to the conclusion that 14-3-3 controls the duration of the arrest and p21 is 
involved in its stabilization11.  
 
 Cell division in M phase depends on the attachment of kinetochores to the spindle 
fibers. These protein structures, located on chromatids, separate the sister chromatids to 
opposite poles of the cell, being this way directly related with the correct separation of 
chromosomes in cells. Therefore, in the spindle checkpoint an evaluation of the attachment 
of the kinetochores is performed2. If these structures are incorrectly attached to the spindle 
fibers, BUB and MAD proteins are sequestered. These proteins form an inhibitory complex that 
will inactivate the anaphase-promoting complex (APC/C)2. 
 Several proteins, known as mitotic kinases, regulate the mitotic spindle. This group of 
serine/threonine proteins encompasses CDK1, PLK, NIMA-related kinases, WARTS/LATSI-
related kinases and Aurora/IPL1-related kinases. The last group, Aurora kinases, is involved 
in the progression of cell cycle from G2 phase to cytokinesis
2. 
   
 As described previously, p53 protein is a major key regulator of G1/S and G2/M 
checkpoints. This protein senses DNA damages and arrests the cycle until this damage is 
repaired or, in the case the damage is too extensive, induces apoptosis. G2/M transition 
involves inhibition of cell division cycle protein 2 (Cdc2) - CDK1 - and, in addition to the 
already discussed mechanisms by which p53 is able to block cell cycle, other targets were 
identified. An example is the repression of cyclin B1 gene by p53 that also contributes to the 
block of mitosis’ entry11. Other mechanisms involve induction of the transcription of the 
reprimo, B99 and mcg10 genes by p53 that leads to G2 arrest and repression of 
topoisomerase II gene that prevents entry into mitosis11. Overexpression of reprimo, a 
cytoplasmic protein, causes arrest of the G2/M transition but its mechanism of action is 
unknown11. On the other hand, topoisomerase II is an important enzyme for DNA 
replication, since it binds to DNA creating DSBs and assists the repair process. This enzyme is 
downregulated by p53 and its inhibition stops cells from entering mitosis11. 
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 An experiment performed by Taylor and Stark (2001) with HCT116 colon cancer cells 
lead them to the conclusion that p53 is not a requisite for the initial G2 arrest but is 
fundamental for a long-term stop11. This is due to the activation of p53-indepent pathways, 
ATM-ATR, discussed above. Other studies suggested that in addition to causing G2 arrest on 
its own, p53 can also prolong the effect of DNA damage on it11. Nevertheless, p53 effects on 
G2/M transition depends on the cell type under study
11. 
 
 Cyclin dependent kinases are periodically activated by cyclins, what drives the cell 
cycle forward. On the contrary, CDK are negatively regulated by CKIs2. Once CKIs act through 
inhibition of the cycle, it is not hard to understand that many of them are tumor suppressors 
in humans and loss of their function is associated with cancer. There are two families of CKIs 
– INK4 and CIP/KIP – whose function is to inhibit the activity of cyclin-CDK complexes. INK4s 
(p15, p16, p18, p19) act by binding to CDKs and CIP/KIP (p21, p27, p57) by binding to 
cyclins2. The INK4 family of proteins inhibits the activity of cyclin D-CDK4 of G1 phase and 
prevents RB phosphorylation2. A protein of this family, ARF (p14ARF in man) also activates 
another important tumor suppressor, p53. ARF sequesters MDM2 (that targets p53 for 
degradation) and stabilizes p53 in response to oncogenic stress, what results in G1/S and 
G2/M arrest
2. The other family of inhibitors are the CIP/KIP family. These inhibit CDK2-cyclin 
E and A and CDK1-cyclin B7. High levels of p21CIP1, major transcriptional target of p53, arrest 
the cell cycle by inhibition of cyclin E-CDK22. Two CKIs, p16INK4a and p27KIP1, are also 
important for the control of the restriction point. They bind and inhibit the activity of cyclin 
D-CDK and cyclin E-CDK, arresting cells in G1
2. 
  
 Control of the cell cycle is also dependent on the degradation of proteins. Two 
complexes of enzymes – SCF and APC/C – control the cycle by promoting degradation2. 
These enzymes are ubiquitin ligases that act on several regulators of the cycle, causing their 
destruction by the proteasome. SCF enzymes regulate the G1/S transition, destroying cyclins 
of this phase and some CKIs that control S phase initiation2. These enzymes are activated by 
p53 and genotoxic stress, targeting regulators like cyclin E and c-MYC, gene commonly 
related with cancer that encodes transcription factors. APC/C enzymes regulate mitosis 
proteins like cyclin B and securin2, being responsible for initiation of anaphase and exit of 
mitosis. 
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1.1.4. Cell Cycle and Cancer 
 The complex mechanisms of cellular regulation portrayed previously serve the 
purpose of avoiding the propagation of errors in populations of cells. They have the ability to 
arrest cell cycle and repair DNA, so that no mutations or aneuploidy spread through cells, 
although most of the times errors may occur. Mutations in two types of genes – proto-
oncogenes and tumor-suppressor genes – are particularly relevant to cancer2. Proto-
oncogenes encode proteins that operate on signaling pathways that stimulate cell division. 
In case of mutation, these genes have a gain of function and proliferation values are 
enhanced, aiding the tumorigenesis process2. Inactivating mutations on tumor suppressors, 
tumor-suppressor genes, also lead to enhance values of proliferation. These are responsible 
for the inhibition of the cell cycle, once they encode proteins involved in regulatory 
pathways (eg. RB and p53 proteins)2. 
 The decision to divide is mainly dependent on the G1 phase. If cells pass the 
restriction point and transit to S phase, cell cycle will occur without any additional stimuli. 
Bearing this in mind, it is expected that, in cancer cells, the G1/S transition control is often 
disrrupted2, making cells independent of mitogenic stimuli. The Rb pathway, whose protein 
phosphorylation is a key event of G1/S transition, is frequently altered in cancer. In fact, 
nearly 90% of human cancers show variations in the RB pathway2. Its non-functionality is 
due mostly to the inappropriate activation of CDK/cyclin or loss of CKIs2. 
 Occasionally, mutations on CDKs occur in cancers. The result on some CDKs, for 
example CDK4 and 6, is to make them unresponsive towards CKIs2. Other effect, in some 
colonic tumors, is the overexpression of CDK1 and 22. Inappropriate activation of CDK-
cyclins, result of deregulation of CDC25, has been found in some cancers. CDC25 
phosphatase family is responsible for CDK activation. Deregulation of cyclins are another 
target for tumorigenesis. For example, high levels of cyclin D1 expression, participant of 
early G1 phase, are often found in many types of cancer, for example colon cancer2. An 
important target for cancer pathogenesis is the dysregulation of cyclins that bind to S-phase 
CDK22, such as E-type and A-type cyclins. These regulate DNA replication and cellular 
proliferation, being high levels of expression associated with aggressive disease and poor 
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prognosis. Overexpression of cyclin B1, regulatory subunit of the G2/M transition, is often 
found in colorectal cancer and is also associated with poor prognosis14. 
 Adding to mutations in the CDK-cyclin mechanism, loss of CKIs is another important 
factor for cancer development, being Rb protein their major target2 once the absence of CKIs 
will increase proliferation. An example of a relevant CKI is p27KIP1, whose downregulation is 
associated with tumor aggressiveness and poor prognosis. In colorectal carcinomas, the 
diminished levels of p27KIP1 are due mainly to increase of proteasome-dependent proteolysis 
rather than gene deletion2. Cells deficient in  p21CIP1 and p53, most common mutated gene 
in human cancers, are not able to arrest  the cell cycle, in response to DNA damage2. p21CIP1 
is a downstream target of p53 that helps to maintain cell survival when DNA damage 
happens. 
 Since cell cycle checkpoints control the progression of the cycle,  their loss is a sign of 
cancer and a common one in humans. In addition to p53, RB and several CKIs, checkpoints 
are also controlled by two DNA damage-response pathways – ATM and ATR-CHK12. These 
signaling pathways function as checkpoint activators after DNA damage. Double-strand 
breaks (DSBs), consequence of the damage in DNA, are repaired by proteins activated by the 
ATM kinase2. Deficiency in these pathways results in DSBs accumulation and genomic 
instability. 
 Cells undergoing cell cycle are targets for cancer chemotherapy, once their DNA is 
more exposed and susceptible during DNA synthesis and cell division9. Because some tumor 
cells, eg. colon cells, present a slower growth rate than others (eg. leukemia), they become 
less susceptible to most anticancer agents. This is counteracted by shifting of G0 cells to G1, 
so they can re-enter the cycle. To do so, debulking of the tumors is performed with surgery 
or radiation9. As a consequence of this reduction of size, the remaining cells are pushed from 
G0 to G1 due to the increase of availability in nutrients and oxygen, among others. These now 
active cells are more susceptible to drug therapy9.   
 
 
1.2.  Cell death mechanisms 
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 As initially discussed, tissue homeostasis is fundamental for survival and the balance 
between life and death has to be carefully made through a variety of processes. In fact, 
about 5x1011 cells are eliminated every day in humans, but a continuous production in the 
bone marrow balances the cellular losses7. Regulation of growth and control of cell division 
was clarified previously. Now, some mechanism that control cellular death will be explored. 
 
1.2.1. Programmed Cell Death – Apoptosis 
 Apoptosis, or programmed cell death, is a common endogenous process in which 
cells order their own destruction in a organized manner. This mechanism is activated 
whenever the organism needs to eliminate some cells or the cell itself senses something 
wrong7, leading to some morphological transformations. The first event is the decrease of 
cell size and consequent aggregation of its components. This is followed by condensation of 
the nucleus and, in some cases, nuclear fragmentation. The final step is the formation of the 
apoptotic bodies7, cell fragments surrounded by cytoplasmic membrane to be phagocytosed 
by leukocytes. Phosphatidylserine, normally located in the inner part of the membrane, is 
expressed in the surface during apoptosis and is recognized by receptors expressed by the 
phagocytes7. 
   
 Caspases 
 Caspases are the executors of apoptosis, cleaving more than 100 different cellular 
targets like inhibitors of DNase and cytoskeletal proteins for example. There are at least 7 
families of caspases that can be classified as initiators or effectors, depending on their 
function7. All caspases are initially inactivated and converted to an active form through 
proteolytic cleavage by other caspases, with the exception of the initiator – caspase 93. This 
is activated by link with Apaf-1, forming the apoptosome that will then start a chain reaction, 
activating downstream effector proteins like caspase 3 and 7, similar in function. Formation 
of this complex requires the release of cytochrome c from mitochondria15. Given the 
importance of caspases to cellular death, their regulation is fundamental to survival. 
Caspases are regulated by a family of proteins, the inhibitors of apoptosis (IAP) family. IAP 
proteins interact directly with caspases, inhibiting their function. The Smac/Diablo and 
Omi/Htr2 proteins released from the mitochondria interfere with the action of IAPs7. 
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 Intrinsic pathway 
 The intrinsic or mitochondrial pathway, represented in Figure 5, is initiated in the 
interior of the cell by any stimuli that causes oxidative stress, mitochondrial disturbances 
and DNA damage16. This apoptotic process is regulated by the Bcl-2 family that acts in the 
mitochondria. Bcl-2 family members are divided into Antiapoptotic Proteins (bcl-2 itself), 
whose function is to inhibit apoptosis and Proapoptotic Proteins, that induce caspase 
activation and promote death7. The balance between these two types of proteins 
determines the fate of the cell. Proapoptotic Proteins are sub-divided into two groups that 
differ in function and extent of homology with Bcl-2. The proapoptotic multidomain proteins 
have three Bcl-2 homology (BH) domains (eg. Bax and Bak) and the BH3-only proapoptotic 
proteins (eg. PUMA and Noxa) only have one7. Bax and Bak members are inhibited by 
antiapoptotic members like Bcl-2. BH3-only members are regulated by signals that induce 
death or survival. Once activated, these proteins work against the antiapoptotic bcl-2 family 
and activate the Bax/Bak multidomain proteins, leading to caspase activation and cell 
death3. Bax and Bak bind to the mitochondria, releasing cytochrome c and other proteins 
like, for example, Smac/Diablo and Omi/Htr2, due to the subsequent membrane 
permeabilization. This promotes the apoptotic process by caspase activation7. 
 
 
 
 
 
 
  
 
 
 
 
 
 Figure 5 – Intrinsic and Extrinsic apoptotic pathways. Image extracted from “Apoptosis signaling proteins 
as prognostic biomarkers in colon cancer: A review”
3 
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 Extrinsic pathway 
 The apoptotic process can also be initiated from the exterior of the cell (extrinsic or 
death receptor pathway) by the activation of death receptors in the surface (Figure 5). Death 
receptors like, for example, FAS and death receptor 4 and 5, are activated by their specific 
ligands (i.e. FasL and TRAIL)3. This link results in the activation of caspase 8 by the 
accumulation of FADD molecule. Once activated, caspase 8 leads to the activation of the 
effector caspases. This pathway is not completely independent of mitochondria. In fact, 
caspase 8 also activates the Bid BH3 only protein, linking this way the two apoptotic 
pathways3. 
  
 p53 function 
 The important role of apoptosis is the elimination of damaged cells. The ATM/ATR 
signaling pathway, main pathway of DNA damages, is mediated by p53. The choice between 
inhibition of the cell cycle and induction of apoptosis depends on the extension of the DNA 
damages. Normally, when apoptosis is a result of p53 mediation the intrinsic pathway is 
activated17. The increase of p53 in response to DNA damage leads to the synthesis of BH3-
only proteins, what consequently causes an increase in the number of apoptotic cells7. P53 
activates several genes important for the execution of the apoptosis’ intrinsic pathway, for 
example NOXA and PUMA. The increase of apoptosis can also be due to the interaction of 
p53 with antiapoptotic proteins. The link between these bcl-2 like proteins and p53 
destabilizes the mitochondrial membrane, causing a release of cytochrome c. In addition, 
p53 mediated apoptosis can occur via the extrinsic pathway, by the induction of genes 
encoding cell surface receptor like death receptor 5 and Fas 17. 
 
1.2.2. Senescence and Necrosis 
 Senescence is a process of biological aging that can end up in cell death. With the 
passage of time, cells accumulate mutations and alterations that cause deterioration and 
even death. The cells’ activity is controlled by the telomeres that protect the ends of the 
chromosomes and determine when the cell has to stop dividing. The length of the telomeres 
is shortened in each division of the cell and when they reach their limit, cells stop dividing. 
Some cells can also undergo senescence in response to stress. Cancer cells are not 
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susceptible to telomere-dependent senescence once they have the enzyme telomerase that 
regenerates telomeres and allow cells to reproduce without temporal control18. 
 
 Another process worth mentioning is necrosis. This is a pathological and disorganized 
process of cell death, consequence of traumatic and acute cellular injury. It can be caused by 
toxic agents or biological agents that have a direct effect on the immune system like fungi, 
bacteria or viruses. After damage of the cell, its constituents are spread into the extracellular 
space, provoking an inflammatory response19. 
 
2. Colon Cancer 
  
 Main focus of this project and 3rd most common cancer in the world, colon cancer is 
the 4th leading cause of death due to cancer, according to the latest statistics20. Risk factors 
for colon cancer encompass increasing age, family history of colorectal cancer, colorectal 
polyps, specific genetic mutations and, most importantly, sedentary and unhealthy diets rich 
in animal fats21. Alteration of genetic markers causes predisposition to this disease and 
individuals with predisposition present a higher risk in the presence of favorable 
environment21. Higher incidence of this type of cancer is typically found in developed 
countries, where the intake of animal fat is coincidently larger22. The first stages of colon 
cancer are often asymptomatic but mortality rates have been decreasing globally in the last 
two decades22. This is the result of better screening processes and detection tools. 
 Before going any further, colon’s function and morphology must be refereed. This 
organ is part of the digestive system, together with esophagus, stomach and small intestine. 
More specifically, colon constitutes the large intestine (with cecum and rectum) and its 
function is to extract water and salt from solid wastes prior to their elimination. Colon can 
be divided into 4 sections, namely the ascending, transverse, descending and sigmoid 
colon23, represented in the figure 6A. Transversally and from the inside out, colon if formed 
by an epithelial layer denominated mucosa, made of epithelial cells which form 
invaginations towards the interior, the submucosa and a layer of muscle. In the external part 
of colon exists a moist membrane called serosa23 (Figure 6B). 
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Figure 6 – Schematic representation of the colon morphology. In A it is represented the four sections of the colon: 1- 
ascending; 2- transverse; 3-descending; and 4- sigmoid colon.  Image B represents a transversal incision on colon with stage 
II cancer, where it can be identified its different layers. 
 
 Colon cancer stages are classified taking into account the invasion of these layers. In 
stage 0, also referred as carcinoma in situ, no invasion is observed and cells on the mucosa 
wall can become cancerous and spread. In the 2nd stage, stage I, cancer is already formed in 
the mucosa and slips to the sub-mucosa. When the tumor has already passed the muscle till 
the serosa without transcending this layer, cancer is at stage II. At stage III, cancer reaches 
the lymph nodes and, finally, at stage IV, it spreads to other organs24. 
 A new approach has been developed in the last years with the goal of reducing colon 
cancer mortality rates. The use of preventive agents is suggested to delay the carcinogenesis 
process and, logically, the safety of the compounds is one of the main concerns. For 
example, curcumin, a common spice in India, was proposed as a chemopreventive agent for 
colon cancer by Johnson and Mukhtar25. The promising results of its activity together with 
the safety and tolerability presented lead to the ongoing clinical trial phase II25. 
 Regarding treatment, chemotherapy plays a central role fighting this disease but the 
diversity of patients’ genetic profiles hampers efficacy. The discovery of drugs that show 
efficacy in all patients motivates the search of more efficient drugs. 
 
2.1.  Carcinogenesis process 
 
 The transformation of normal cells into carcinogenic ones is a multistep process that  
occurs through an extended period of time. This process is the result of the accumulation of 
several genetic mutations which change the mucosa, leading to the formation of carcinomas. 
In fact,  about half of the human colon tumors show a mutation in the Ras oncogenes, which 
stimulates proliferation6. Many external and internal factors contribute to this 
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transformation like carcinogens, but the most critical factor is diets rich in animal fats, as 
discussed previously.  
 The carcinogenic process (Figure 7) can be divided into 3 parts. The first is the 
initiation, where the cells’ genetic information is altered in consequence of mutations due to 
carcinogens4. In this stage of development, cells gain an intrinsic proliferative capacity that 
cannot be controlled, due to mutation on genes like APC4. Promotion of the initiated cells is 
the 2nd phase and leads to abnormal cell division and formation of cell masses, neoplasms, 
that are now detectable. Accumulation of mutations on genes like p53 and KRas happens 
due to the continuous exposure to genotoxic agents4. Tumor growth relies on the delicate 
balance between the number of cells in proliferation and the ones directed to death 
pathways9. Colon tumors have low growth rates, which is due to a small unbalance, being 
that the cellular production only exceeds cell losses by 10%9. As said previously, this growth 
rate has serious effects on the tumors susceptibility to chemotherapy. The last stage is the 
progression. In this, tumors turn malignant and gain the ability to invade other tissues and 
organs and create metastases4. 
 
Figure 7 – Classical pathway for colon cancer progression
4
. In the scheme is represented some key genetic alterations 
responsible for the carcinogenesis process. Extracted from “Dynamics of cancer – Incidence, Inheritance and Evolution”. 
 
 The majority of colon tumors follow this pathway of genomic instability. These have 
chromosomal instability (CIN) – CIN tumors - and present allele losses and aneuploidy26. 
Most solid tumors present CIN but its causative genes are not identified yet. The other 
pathway - microsatellite instability (MSI) - is due to defects in one of the mismatch repair 
system (MMR) genes. This less common pathway is only present in 15% of colorectal cancers 
and is characterized by several DNA mutations and diploidy. The most frequently inactivated 
genes seen in MSI are MLH1 and MSH2. MSI leads to the HNPCC syndrome, which, 
consequently, follows different genetic steps of cancer progression26. 
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 The study of the genetic profiles of colon tumors lead to their categorization into the 
following groups: sporadic, inherited (about 10%) and familial (about 25%). Focusing on the 
syndromes with hereditary interference, the two most common forms are the familial 
adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC)25. The 
FAP syndrome is the result of germline defects on the adenomatous polyposis coli gene 
(APC) which is related with the initiation of tumors. APC is involved in the transmission of 
signals to the nucleus and patients with this mutation show predisposition to cancer and a 
high initiation rate of adenocarcinomas. About 30% of the FAP cases do not have hereditary 
origins and arise de novo27. Due to the large number of adenocarcinomas characteristic of 
this syndrome, it is probable that some of them progress and become malignant with the 
assistance of additional mutations in other genes like p53. The most common inherited 
cancer susceptibility is hereditary nonpolyposis colorectal cancer syndrome (HNPCC), the 
result of autosomal dominant mutations in a MMR gene, as described previously. These 
mutations result in an enhancement of the tumors’ progression rate27 and accounts for 15% 
of colon cancers7. 
 
2.2.  Growth signaling pathways 
 
 Cell homeostasis and maintenance depends on the delicate balance between cell 
division versus senescence and survival versus death. These processes are induced by 
several regulatory signals that bind to receptors in the cell membrane. Regulatory growth 
signals can be either local – paracrine - produced by the own cell, or act at distance through 
the circulation - endocrine. In addition they can also be positive or negative28. Normally 
these GF are integrated in the G1 phase of the cell cycle before the restriction point, deciding 
if the cell will either divide or arrest. Cancer cells do not depend on this regulation, creating 
their own growth signals28. These signals, commonly referred as GF, can be classified into 
three groups: mitogens, that promote cell cycle entry by induction of the G1/S transition; 
growth factors, that promote protein synthesis, resulting in an increase of cell mass; and 
survival factors, that promote survival by elimination of apoptosis. Mitogens act on cyclin D- 
CDK complexes increasing their activity, and pushing the cell cycle forward28. Contrary, 
cytostatic factors inhibit replication. TGF-β, member of the Transforming growth factor (TGF) 
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family is an example. Regulation signals are integrated by different pathways, which serve as 
a communication road to the nucleus28. MAPK/ERK and PI3K/Akt signaling pathways (Figure 
8) are frequently altered in colon carcinomas, due to Ras mutations for example, breaking 
the cell equilibrium and causing a concomitant increase of cell proliferation and decrease of 
apoptosis. 
 
 MAPK/ERK signaling pathway 
 The commonly known as MAP kinase (MAPK) pathway, schematized in Figure 8, is 
part of a larger signaling family, the MAPK signaling pathways family. In addition to this 
subfamily of kinases regulated by extracellular signals – MAPK/ERK – there are two others, 
the JNK and p38 pathways29. The Mitogen-activated protein kinases (MAPK) protein was 
originally denominated as ERK, once it regulates extracellular signals, being this pathway also 
known as RAS-RAF-MEK-ERK pathway. 
 This pathway, deregulated in about 30% of cancers, is one of the most important for 
cell increased proliferation and decreased apoptosis, creating a chain of communication 
between external signals (eg. growth factors) and the nucleus in a series of protein 
activations29. Phosphorylation of ERK protein (pERK) is a indicator of the activation of this 
pathway, which can be due to the upstream participants in the transmission of the signal, 
like KRAS and BRAF30. Mutations on 
these genes lead to uncontrolled 
proliferation. After activation of RAS by 
external signals, it binds to RAF and 
consequently activates MEK, which will 
then phosphorylate ERK29. This will 
provoke a response by the nucleus like, 
for example, cyclin D synthesis7. Since 
this pathway is frequently altered in 
colon cancer it provides excellent 
investigation targets when studying the 
effect of compounds in cancer cells. 
 
 
Figure 8 – MAPK/ERK and PI3K/Akt pathways. 
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 PI3K/Akt signaling pathway 
 Another important and commonly altered pathway in colon cancer is the PI3K/Akt 
signaling pathway, schematized in Figure 8. This is one of the major intracellular pathways 
promoting cell survival. Deregulation of this pathway also leads to an increase of 
proliferation and decreased of apoptotic cells30. 
 After activation of PI3K by Kras, for example, Akt is activated by phosphorylation of 
the membrane phospholipid PIP2, which is then turned into PIP3. Akt phosphorylation is a 
good indicator of the activation of this pathway. This process results in the activation of 
mTOR that promotes cellular growth. A key substrate of Akt is the Bad protein, member of 
the BH3-only proapoptoctic proteins of Bcl2 family7. 
 
3. Colon Cancer Treatment 
 
 Depending on the stage at which the tumor is detected and the patient itself, 
treatment of colon cancer can take an active form of action, by fighting and trying to find a 
cure for this disease or a palliative action. When this type of cancer is diagnosed early, 
surgery is often the treatment of choice. In addition to the surgical removal of the tumors, 
chemotherapy is normally used with the goal to eliminate remaining cancer cells that can 
spread through the organism. The discovery of an active drug effective on all the different 
genetic profiles found in colon carcinomas poses as a serious challenge. 
 
3.1. Drugs approved for chemotherapy 
 
 Fluorouracil (5FU), represented in Figure 9B, is probably the most widely used drug 
for chemotherapy in several types of cancer. This FDA approved antimetabolite is used in 
advanced colon cancer that has recurred or not gotten better. 5FU has to be converted in 
vivo into its active form, fluorodeoxyuridine triphosphate (FdUTP) so it can bind to RNA and 
produce the desired effect. The incorporation of 5FU into RNA interferes with DNA synthesis 
by inhibition of thymidylate synthase (TS)31, enzyme responsible for the generation of 
thymidine triphosphate. This is considered the main mechanism of action of this drug. 
Inhibition of TS is only possible during S phase of the cell cycle and only a few cells are found 
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in this phase, what would decrease 5FU’s effect if it were not for other mechanisms of 
action32. A second mechanism of action of 5FU relies on fluorodine triphosphate (FUTP), 
another active metabolite. This replaces uracil and is able to incorporate RNA, inhibiting its 
processing and, consequently, cell growth. In order to overcome resistance to 5FU, 
biochemical modulation of its metabolism was examined with several purines and 
pyrimidines, but only some of them were successful31. In a previous study, the effect of 5FU 
was assessed in two isogenic cell lines of colon cancer, HCT116 (p53-wt) and HCT116 (p53-
null) with a complete knockout of p53, which allowed to ascertain the importance of p53 for 
the activity of 5FU. It was concluded that HCT116 (p53-null) cells were resistant to the effect 
of 5FU, making p53 of extreme importance to the efficiency of this drug33. In addition, it 
became clear the dependence on p53 of 5FU’s mechanism of apoptosis induction. In HCT116 
(p53-wt) cells, where the compound is active, high levels of apoptosis were observed. In 
opposition to this, in HCT116 (p53-null) cells 5FU had no effect. This was corroborated by the 
cleavage of PARP-1 protein, which was only cleaved in HC116 (p53-wt)33. 
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 Capacitabine (Figure 9A) is another FDA approved compound for treatment of colon 
cancer in stage III patients who already had surgery. It is a prodrug, what means that serves 
as a precursor for the desired drug, being active by the normal metabolism of the organism. 
This fluoropyrimide carbamate is activated by thymidine phosphorylase of tumor cells, which 
Figure 9 – Chemical structures of FDA approved drugs for CRC chemotherapy. Image obtained with ChemDraw 
software. 
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transform it into active 5FU. Consequently, the same mechanism of action as 5FU is to be 
expected for this small molecule, leading to inhibition of DNA and protein synthesis and cell 
division34.  
 Patients with advanced or recurrent colon cancer at stage III can also be administered 
oxaliplatin (Figure 9E). This FDA approved drug is a organoplatinum complex that results in 
the inhibition of DNA replication and transcription with non-specific cytotoxicity. This is the 
consequence of the formation of inter and intra- strand cross links in DNA, which prevent 
DNA replication and transcription, what ultimately results in cell death35. The inexistence of 
a specific target results in low efficacy of treatment and strong side effects. 
 Another example is irinotecan (Figure 9F) used for patients that present metastases 
or which cancer has recurred. Irinotecan is also a prodrug, being converted into its 
biologically active metabolite SN-38. This antineoplastic small molecule inhibits the activity 
of topoisomerase I which leads to DNA breaks. The end result is the inhibition of DNA 
replication and induction of apoptosis36. 
 Regorafenib (Figure 9D), developed by Bayer, is used for metastasized colon cancer in 
patients that already received other treatment without success. It targets VEGFR2 and 
PDGFR, preventing the formation of new vessels37. 
 Leucovorin (Figure 9C) is used as a palliative treatment for chemotherapy. It is 
administered in addition with other antineoplastic drugs like 5FU. Leucovorin contradicts the 
toxic effects of these drugs, lowering their side effects. In addition allows their antineoplastic 
activity38. 
 When CRC carcinomas gain the ability to spread and invade other organs, a different 
course of treatment has to be administered. So, in order to prevent the formation of 
metastasis, humanized monoclonal antibodies are used, namely Bevacizumab, Cetuximab 
and Panitumumab. The first antibody is directed against VEGFs (antiangiogenic) and the last 
two against EGF receptors(antineoplastic)37. A more recent drug approved by FDA against 
angiogenesis is Aflibercept. This recombinant protein is a VEGF inhibitor used as a second-
line theraphy37. 
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3.2. Drugs under development 
 
 Being cancer a complex disease that results from several mutations and cellular 
desregulations, the discovery of new and more effective compounds is a arduous task. 
Several processes can interfere with the cell’s regulation and no compound is effective in all 
patients. So new drugs are synthesized everyday with different cellular targets in mind, a 
classic approach in drug development. 
 Several oncogenes commonly mutated in colon cancer like BRAF, KRAS, PI3K and 
SMAD, for example, are associated with lack of response to anti-EGFR therapies like 
Cetuximab and Panitumumab37. As a consequence, downstream components of these 
signaling pathways have become targets for drug development and small molecule inhibitors 
are already under clinical trials (Figure 10). Relatively to the MAPK/ERK pathway, two 
compounds, Selumetinib from Array BioPharma, and PD-0325901, from Pfizer, are under 
phase II and I, respectively, of clinical trial. These small molecules target the downstream 
proteins MEK. The PI3K/Akt pathway was also a target for drug development. BEZ235 and 
BKM120 molecules from Novartis and PX-866 from Oncothyreon are under phase I (BEZ235) 
and II of clinical trials and target the PI3K protein. Nevertheless, these drugs can become 
metastatic inducers depending on the proapoptotic tumor suppressor status of the tumor37. 
LOR-253, a compound from Lorus Therapeutics under clinical trial phase I, targets a different 
pathway, the WNT/β-catenin pathway. Disruption of this pathway causes a consistent 
growth inhibition and apoptosis on colon cancer. One way to interfere with this pathway is 
to alter the levels of Kruppel-like factor 4, which inhibits the expression of β-catenin. This is 
achieved by the inhibition of MTF1 that increases the levels of Kruppel-like factor 437. 
 Drug discovery for the prevention of angiogenesis is also an intended goal. Some new 
compounds, Tivantinib from ArQule, Brivanib from BMS and Vatalanib from Bayer/Novartis, 
are being tested (Figure 10). These target proteins related with the formation of new vessels, 
namely MET (Tivantinib), VEGFR2 (Brivanib) and VEGFR1-3 (Vatalanib). With the exception of 
Tivantinib, which is under phase II, the other two drugs are currently under phase III of 
clinical trials. A recently phase III trial was initiated with TAS-102 (Figure 10). This drug is a 
combination agent constituted with a pyrimidine analog and a thymidine phosphorylase 
inhibitor (TPI). TAS-102 inhibits the thymidine phosphorylase, a potent angiogenic factor. 
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 Epigenetic mutations are also frequently associated with cancer. For that reason, the 
development of epigenetic drugs is a aim of drug discovery. The inhibitor of histone 
deacetylase (HDAC), Reminostat from 4SC, is currently under clinical trial phase II37. 
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 Figure 10 – Chemical structures of compounds under clinical trials for CRC chemotherapy. Image obtained with 
ChemDraw software. 
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 Colon cancer is a major cause of cancer related death in developed countries. Despite 
the variety of drugs available, treatment efficacy is still reduced for some patients, 
particularly those presenting p53 deficiencies, which drives drug discovery research. 
 The main goal of this project is to identify a new compound with anticancer activity in 
colon cancer. Previously studied compounds, belonging to a family of nitrogen heterocycles, 
showed activity in HCT116 (p53-wt) colon cancer cells. It is now intended to enhance their 
anticancer potential by the study of the activity of a new set of compounds derived from 
them, using HCT116 (p53-wt) cells. IC50 values will be determined for the compounds that 
present higher activity. Concomitantly, a  structure activity relationship (SAR) study will be 
made in order to unveil the effect of the substituents on the activity of the compounds. 
 Another important aim of this project is the assessment of the compounds’ activity in 
the absence of functional p53 and KRas, normally associated with tumor resistance. To do 
so, compounds will be tested with HCT116 (p53-null) cells, with a complete knockout of p53, 
and CO115 cells, with an activating mutation on BRaf and KRas wildtype.  
 The mechanism of action of the most promising compounds is also a point of interest 
and it will be investigated in order to understand their interaction with the cell. This will be 
achieved by the assessment of the compounds effect on the induction of apoptosis and cell 
cycle progression. 
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 In order to analyze the potential anti-carcinogenic effect of this family of compounds 
on colon cancer cells, several incubations of 48h were made with the selected compounds. 
After the incubations, different tests were performed depending on the desired parameters 
to analyze, described below. 
  
1. Test compounds and reagents 
 
 All the compounds used in this project were kindly provided by the Chemistry 
Department of this university and synthesized by the group of Professor Maria Alice 
Carvalho. Stock solutions were made by dissolution of the compounds into dimetilsulfoxide 
(DMSO) and stored in aliquots at -20OC. The concentrations of the stock solutions ranged 
from 300μM to 10 mM depending on the solubility of each compound. Compounds unable 
to dissolve at concentrations below 300μM were rejected from testing. Intermediate stock 
solutions were prepared taken into account the desired concentrations to be tested. Prior to 
incubation, stock solutions were diluted with culture medium so that the desired test 
concentration was reached, in such a way that the DMSO concentration did not surpass 0.5% 
(v/v), which otherwise would damage the cells. 
 Primary antibodies for the western blot assay were purchases from: anti-phospho-
Akt (1:2000) and anti-phospho-ERK (1:2000) from Cell Signaling (Danvers, MA, USA);, anti-
KRas (1:250), anti-PARP1 (1:500) and anti-phospho-JNK (1:500) from Santa Cruz 
Biotechnology, Inc.; and anti-β-actin from Sigma-Aldrich. Secondary antibodies HRP donkey 
anti-rabbit and sheep anti-mouse were purchase from Cell Signaling. 
 
2. Solubility assay 
 
 The compounds’ solubility was analyzed starting with the highest concentration 
intended to be tested. For each compound it was prepared a solution with 1mL of PBS 
(phosphate buffered saline) and 5μL of the highest stock concentration (5mM), which was 
kept at 37oC for 24h. Posteriorly to this incubation, samples were observed to see if any 
crystals have been formed. If the solutions proved to be clear, they were considered suitable 
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for biological tests. On the other hand, if it was visible the presence of crystals in suspension, 
another incubation was performed, in the same conditions, at a lower concentration. This 
procedure was repeated at consequently lower concentrations until no crystals were 
observed. Compounds that were not soluble at the range of concentrations chosen to be 
tested were rejected from biological testing.  
 
3. Cell lines and Culture 
 
 In this project, three human colon carcinoma derived cell lines with different genetic 
backgrounds (Table 1) were used as models to examine the effect of the compounds. The 
main cell line used in this project was HCT116, mutated in the codon 13 of the RAS proto-
oncogene and wild type for p53 (p53-wt). In order to examine the role of p53, an isogenic 
HCT116 cell line was also used with a complete knockout for p53 (p53-null). These two cell 
lines were kindly provided by Dr. Vogelstein39. The other colon cancer cell line used, CO115, 
has an activating mutation on BRAF whereas Ras is wild type (Ras-wt) and was kindly 
provided by Dr. Raquel Seruca (IPATIMUP, University of Porto, Portugal). 
 
Table 1 – Genetic profile of CRC cell lines used in this project. 
 Altered gene expression due to mutations 
CRC Cell Lines EGFR KRas BRaf p53 
HCT116 (p53-wt)     - - 
HCT116 (p53-null)     - X 
CO115 - -   - 
 
 Maintenance of the cells in culture was achieved in 25 cm2 polystyrene flasks with 
RPMI-1640 medium (Sigma-Aldrich) supplemented with 6% of bovine fetal serum (FBS), 1% 
antibiotic-antimycotic solution, 10mM Hepes, 0.1 mM sodium pyruvate and 2 g/L sodium 
bicarbonate. Medium and antibiotic solutions were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Cells were kept in a Sanyo COM-17 AIC incubator at 37oC in a humidified 
atmosphere with 5% CO2. Handling of the cells was done in a sterile environment using 
laminar flow chambers: Holten Lamin Air HBB 2448 or Telstar Bio II A. 
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3.1.  SubCulture 
 Once cells reached a confluent state, a small amount of them (0.5×106 cells for 
HCT116 p53-wt and p53-null and 1×106 for CO115) were transferred into a new T25 culture 
flask, so they could grow. To do so, cells were washed with PBS, in order to eliminate 
possible remains of serum molecules, followed by the addition of a trypsin-EDTA solution, 
responsible for breaking the connections between the cells and the bottom of the flask. This 
reagent was acquired from Sigma-Aldrich, St. Louis, MO, USA. After a 5 minutes incubation 
at 37oC, fresh culture medium was added to the flask in order to inactivate the trypsin. This 
way, it was obtained a cell suspension to be used in experiments and/or to grow into new 
flasks after cell count. 
 
4. Cell count 
 
 Cell count is fundamental for plating and other procedures where it is required to 
know the specific concentration of cells in suspension. To count the number of cells, 
Neubauer Chambers were used with a solution of trypan blue 0.4% (p/v) diluted 1:1 with the 
cell suspension. Neubauer chambers are thicker crystal slides with 30x70mm of size and 
4mm of thickness covered with a glass coverslip40. In this project it was used double 
chambers, which means that the chamber has two counting areas and, consequently, two 
counting grids. Each grid has 3x3mm in size, with 9 square subdivisions of 1mm. The distance 
between the bottom of the chamber and the cover is of 0.1mm40. It is this area that 
determines the volume of sample that can be analyzed (1x10-4 mL/mm3). After counting the 
number of cells in the four major squares, the mean of the values was calculated and 
multiplied by the dilution factor, in case trypan blue was used. The concentration was 
calculated by dividing this value by the volume of sample analyzed (1x10-4 mL). Cell counting 
was done using an inverted optical microscope Olympus CK2.  
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5. Cell Plating 
 
 In order to correctly study the effect of the different compounds, it is necessary that 
the number of cells in each condition is equal. This is achieved by plating of a fixed 
concentration of cells. To do so, it is necessary to know the concentration of the initial cell 
suspension and, from this, a new suspension is made with the desired cell concentration 
(0.6×105 cells/mL for HCT116 p53-wt and p53-null and 1x105 cell/mL for CO115). For the 
cellular viability assays, cells were plated into 24-multiwell culture plates (0.5 mL/well), for 
the nuclear condensation assays platting was done on 12-multiwell culture plates 
(1mL/well), and for flow cytometry and Western blot assays, cells were platted into 6-
multiwell culture plates (2mL/well). Plates were kept at 37oC and 5% CO2 for 48h before 
incubation with the test compounds, to allow cell adhesion and growth. To eliminate any 
possible interference of DMSO, each individual plate had at least one control with DMSO at a 
concentration not higher than 0.5% (v/v). Incubation of cells with compounds was also done 
at 37oC in a CO2 incubator. 
 
6. Microscopic observations 
 
 Images of the cells after incubation with the compounds were obtained through an 
inverted optical microscope Olympus IX71 with DP72 camera in phase contrast mode. For 
the nuclear condensation assays, the same microscope was used with the DAPI fluorescence 
filter, which enabled the identification of DNA and observation of the cells’ apoptotic state 
caused by the compounds.  
 
7. MTT assay 
 
 To analyze cell growth, cell viability was assessed through the colorimetric assay of 
MTT reduction, which is a fast, objective and reliable method, as previously described41. 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), an yellow tetrazolium 
salt, was purchased from Sigma-Aldrich. Aliquots of 5 mg/mL were made with PBS, in the 
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absence of light, and stored in aliquots at -20oC. The MTT reduction assay is based on the 
fact that viable cells are able to reduce MTT into formazan crystals, unlike dead cells. This 
reaction is carried out by active reductase enzymes, namely mitochondrial enzymes 
succinate-dehydrogenase, non-functional in dead cells once they do not have functional 
mitochondria, which makes them unable to reduce MTT42. The formazan crystals have a 
characteristic purple color that, after dissolution with DMSO/Ethanol, can be measured by 
spectrophotometry. Taking this into account, a directly proportional relationship can be 
established between the number of viable cells and the color of the solutions, where wells 
with more viable cells result in solutions with a more prominent color.  
 After 48h of incubation with the test compounds, 50 μL of MTT (5mg/mL) was added 
to each well of 24 wells plates, which were then incubated for another 30 minutes at 37oC, 
5% CO2. Posteriorly to this incubation with MTT, the culture medium was removed from the 
wells and the crystals were dissolved with DMSO/ethanol (500μL) for following analysis. 
These colorful solutions were pippeted onto 96 wells plates (200μL per well) and their 
absorbance was read in the spectrophotometer SpectraMax Plus384 Microplate Reader – 
Molecular Devices at 570 nm (with background subtraction at 690nm)42. As blank, 
DMSO/ethanol solutions were used. Results were expressed in percentage relative to 
control. In order to select the best compounds of the family under study, all of them were 
incubated at the same concentration (10 μM), with a few exceptions at lower 
concentrations, due to solubility issues. The results were expressed as mean from at least 3 
independent experiments. Compounds that presented the lowest cellular viability were 
selected to continue in the study and, posteriorly, their IC50 was calculated using this same 
method. To do so, each compound was incubated at various concentrations and data from 
several experiments was arranged and expressed relatively to control. After data analysis 
using the GraphPad Prism 4.0 software it was possible to see the behavior of the compounds 
and to determine the IC50 value of each one. Compounds with the lowest values of IC50 were 
chosen, once again, to continue with the following assays. 
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8. Nuclear Condensation assay 
 
 To examine the possible apoptotic effects of the selected compounds on the cell lines 
under study, the nuclear condensation assay was performed. The objective of this assay is to 
identify apoptotic cells through Hoechst DNA staining. Apoptotic cells suffer a series of 
morphological changes that allow their identification like their decrease in size and 
aggregation of their components, condensation of the nucleus and the formation of the 
apoptotic bodies7. With this test is easy to find out the number of cells that suffer apoptosis 
due to the compounds’ effects and their respective percentage in each sample. 
 Cells were incubated with the compounds for 48h in 12 wells plates, time after which 
both floating and attached cells were collect to falcons and washed with PBS. To do so, 
falcons were centrifuged two times in a Sigma 2-16K centrifuge at 500g for 10min and pellet 
was resuspended in 500μL of PBS. Then, cells were fixed with 4% paraformaldehyde (PFA) 
(2mL/sample) and kept in ice for 20min. Finally, they were washed once again with PBS, 
centrifuged as above and  all the pellet was resuspended in 500μL of PBS. Samples were 
then ready to be attached to a polylysine coated slide using a cytospin. Once the apparatus 
of the Shandon Cytospin 4 (Thermo Scientific, Waltham, MA, USA) was assembled, samples 
were loaded onto the hoppers and centrifuged at 500rpm for 5min. The slides were washed 
with PBS two times for 5min. In the last step of this assay, slides were put in a dark chamber 
and incubated for 10min with 20μL of Hoechst stain. This stain was purchased from Sigma-
Aldrich and kept at 4oC in aliquots of 0.5 mg/mL. This BisBenzimide, used as a fluorescence 
stain for DNA, was diluted in PBS (1:100) prior to testing, so that the concentration in the 
samples was 5 μg/mL. After the incubation time, it was added 6μL of glycerol 50% (v/v) in 
order to fix the lamella to the slide. Finally, with the help of an inverted microscope with 
proper fluorescence filter, it was possible to identify apoptotic cells and calculate their 
percentage from the ratio between them and the total number of cells. For each condition, a 
minimum of 400 cells was counted. Apoptotic cells were identified by the presence of 
fragmented and/or shrunken nuclei (Figure 11). Data was organized taken into account all 
the conditions under study and their respective values of percentage of apoptosis. 
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Figure 11 – Representative image of a nuclear condensation experiment. In the image can be identified normal cells (A) as 
well as apoptotic cells (B). Image obtained with an inverted optical microscope Olympus IX71 and DAPI fluorescence filter. 
 
9. Cell Cycle Analysis by Flow Cytometry 
 
 The flow cytometer was used with the aim of study the effect of the test compound 
on the progression of the cell cycle. Several types of analysis can be performed with this 
technique, including detection of total DNA content for cell cycle analysis. With this test it 
was possible to analyze the cell cycle progression after treatment of the cells with the 
compounds, what gave us a more clear idea about their mechanisms of action43. Flow 
cytometry is a technology based on the ability of a cytometer to detect and count cells 
individually, with the aid of a laser, classifying them. Cells and other particles have to be 
suspended in a fluid as they pass the electronic detection mechanism. As they are conducted 
through this liquid stream, cells reach the interrogation point, also denominated analysis or 
observation point, where they are intersected by a laser. Today’s lasers can be either gas 
(argon ions; helium-neon laser) or solid-state lasers (red or green diode or blue and violet 
lasers), being the most common the argon ion lasers43. In this point, the beam of light is 
scattered by the particle. Fluorescent chemicals present in the particles are also excited and 
emit light in a longer wavelength than the light source. Fluorochromes can also be used to 
identify apoptotic cells. The scattered and fluorescent lights are then detected by a set of 
detectors that gather the information about the particles and  transmit them to a 
computer43. Typically, there is one detector in front, the forward scatter (FSC) and several 
perpendicular scatters, the side scatters (SSC) as well as fluorescent scatters. The FSC 
B 
A 
B 
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analyses the volume of the cell and the side scatters give information about the interior of 
the cells, like the shape of the nucleus for example. The group of detectors is accompanied 
by a ADC system that converts the signals from light to electrical signals so they can be 
processed by a computer. Finally, signals are analyzed by a computer where they can be 
interpreted43. Data is plotted taking into account the number of cells and the fluorescence 
intensity, which is proportional to the DNA content7. 
 To perform this assay, cells were incubated with the compounds for 48h. After this 
time, cells from each well were trypsinized and collected into falcons, in which they were 
submitted to a centrifugation at 500g for 3min in a Sigma 2-16K centrifuge. Pellet was 
resuspended in 500 μL of PBS and kept in ice for 15min. Posteriorly, another centrifugation 
was performed in the same conditions, in order to wash the cells with PBS. The resuspended 
pellet from this centrifugation was then pipetted into ice-cold 96 ethanol and maintained in 
ice for at least 15 minutes with the goal of fix and permeabilize cells. This step inhibits 
cellular activity and allows the dye to enter the cell while it remains intact43. Samples are 
then vortexed and centrifuged two more times at 700g for 3 minutes. After resuspension of 
the pellet, 50 μL of RNAse A is added to all samples, which are then incubated for 15 minutes 
at 37oC, in order to destroy all RNA from the cells. This step certifies that the fluorescent dye 
only binds to DNA and results are more reliable. The last step is the addition of 60 μL of 
propidium iodide (PI) from Sigma-Aldrich per sample, a DNA-binding fluorochrome that 
intercalates the DNA double helix. After this procedure, samples were ready to be analyzed 
in the Coulter Epics XL Flow Cytometer (Beckman Coulter Inc., Miami, FL, USA), where at 
least 40000 single cells were counted per sample. Data was then fitted using the FlowJo 
Analysis Software (Tree Star Inc., Ashland, OR, USA), through the mathematical Watson 
Pragmatic model44. 
 
10. Western blot assay 
 
 The compounds’ effect at a molecular level was studied resorting to the western blot 
method. In this technique, a sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
(SDS-PAGE) was first used in order to separate the different cellular proteins. After 
incubation with the compounds, proteins are extracted from cells and protein concentration 
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quantified. Samples are then prepared in a way that the same quantity of proteins is loaded 
in all conditions, making possible the comparison between samples. Protein preparation 
involves the addition of a denaturant agent that linearizes proteins and grant them a 
negative charge proportional to their mass45. As said previously, the denaturant agent used 
was sodium dodecyl sulfate (SDS), an anionic detergent that denaturants non-disulfide-
linked tertiary and secondary structures. In order to further denature proteins, heating of 
the samples in the presence of dithiothreitol (DTT) is a usual step. Heating of proteins 
promote their denaturation, as well as DTT, which is able to reduce disulfide links, not 
denature by SDS, and break quaternary structures45. Only after this treatment proteins can 
be separated accordingly to their mass and length. After loading the samples onto the 
electrophoresis gel, an electric field is applied, forcing ions to move from the negatively 
charged electrode - the cathode - to the positive one - the anode. This results in the 
migration of proteins (with negative charge) towards the anode45. Polyacrylamide gels 
consist, as the name implies, in acrylamide and bisacrylamide. Polymerization is possible due 
to bisacrylamide that can make cross-links between two polyacrylamide molecules. 
Ammonium persulfate (APS) and tetramethylethylenediamine (TEMED), a source of free 
radicals and a stabilizer respectively, are responsible for the beginning of the polymerization 
reaction, being for this reason the last components added45. Ethanol is poured over the 
resolving gel with the goal of removing possible bubbles and smooth the surface. After 
sample loading and start of the run, protein migration results from the action of chloride and 
glycinate ions present in the gel. Chloride ions run faster than the proteins linked with SDS 
and glycinate ions run in front of the running buffer, creating two barriers that restrain the 
proteins and force them to move through the staking gel. In the transition between the 
stacking and resolving gel the pore size decreases, leading to the separation of the proteins 
based in their molecular weight (MW) only45. Throughout this process, denatured proteins 
are separated accordingly to their mass, taken that small molecules will fit through the pores 
of the gel more easily than large ones. The second step of western blot is the transfer of the 
proteins from the electrophoresis gel into a membrane (blotting), where they become 
immobilized45. In order to detect the proteins of interest, specific antibodies for each one 
are used. Unoccupied binding sites of the proteins are occupied to prevent non-specific 
binding of the antibodies. After a first incubation with these primary antibodies, a second 
incubation is made with the secondary antibodies, which specifically bind the primary type 
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and possess a detectable group. This group is responsible for the visualization of the bands 
after incubation with the revelation solutions and detection45. The last step is then the 
detection of the protein bands. The choice of detection method depend on the imaging 
equipment available, being the chemiluminescence detection system the elected in this 
project. With these results, the effect of different drugs on different proteins’ expression can 
be assessed. 
 This assay was performed after incubations of 24/48h with the compounds. Cells 
were then washed with PBS and lysed for 15min at 4oC with ice cold RIPA buffer (1% NP-40  
in 150 mM NaCl, 50 mM Tris-HCl (pH 8), 2 mM EDTA) containing 1 mM phenylmethylsulfonyl 
fluoride (PMSF) (Roche, Mannheim, Germany), phosphatase inhibitors (20 mM NaF and 20 
mM Na2V3O4) and protease inhibitor cocktail (Roche). After the successful extraction of the 
proteins, their concentration by quantified through the Bio-Rad DC protein assay (Bio-Rad 
Laboratories Inc.). Bovine serum albumin (BSA) was used as the standard protein. From each 
sample, 20μg of protein was prepared and loaded onto the polyacrylamide gel. After 
electrophoresis, proteins were electroblotted to Hybond-P polyvinylidene difluoride 
membranes (GE Healthcare), which were then blocked in TPBS (PBS with 0,05% Tween-20) 
with 5% (w/v) of non-fat dry milk. When all non-specific binding sites were occupied, 
membranes were incubated with the primary antibodies overnight and then with the 
secondary antibodies for 1h. Immunoreactive bands were identified using the Immobilon 
solutions (Milipore, Billerica, MA, USA) and the chemiluminescence detection system, 
ChemiDoc XRS (Bio-Rad Laboratories, Inc.). Intensity of the bands was quantified with the aid 
of the Quantity One software (Bio-Rad Laboratories) and β-actin was used Gas a loading 
control. 
 
11. Statistical analysis 
 
 All experiments were performed independently and at least three times, after which 
data was treated as means ± SEM. Results were evaluated statistically using the one-way 
ANOVA followed by a Dunnet’s post-test. Statically differences were considered significant 
when p-values < 0.05 (* p≤0.05; ** p≤0.01;***p≤0.001). For the IC50 calculus of the various 
compounds, a nonlinear regression was used. With this analysis it was established a 
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relationship between the concentrations of the inhibitors (in logarithm) and their response 
in cellular viability. Outliers were excluded from the analysis in order to increase the 
accuracy of the analysis. All the statistical analyses were performed through to the GraphPad 
Prism 4.0 software (San Diego, CA, USA). 
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 With the aim of assessing the anticarcinogenic potential of a variety of nitrogen 
heterocycles, several analyses were performed. The experimental work started with the 
compounds’ screening, through their analysis of cellular viability by the MTT assay, using the 
HCT116 (p53-wt) cell line. The most active compounds, identified in the screening, were 
selected in order to study their mechanisms of action. To do so, the effect of the compounds 
on cellular proliferation/induction of death and on the progression of the cell cycle was 
analyzed. Expression of related molecular markers was assessed by western blot. 
 
 
1. Compounds’ biological activity 
 
1.1. Screening in HCT116 (p53-wt) cells. 
 
 In order to ascertain the effect of the compounds on cellular viability by the MTT 
assay, these were incubated at 10μM for 48h with HCT116 (p53-wt) cells. This cell line was 
chosen to perform this assay, as it was the cell line used in the previous investigation46. 
Cellular viability was assessed through the performance of the MTT assay. All the tested 
compounds have the same central structure, the heterocyclic nucleus (Fig. 12a). Around the 
central structure different substituents R and R1 were incorporated. In order to assess the 
importance of the R1 group’s position in the heterocyclic structure, the substituent R1 was 
introduced in a different position of the heterocyclic nucleus (Fig. 12b). 
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Figure 12 – Central structure of the compounds. All the compounds have the same central 
structure (a) with the exception of compound 36 (b). 
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 All the compounds were tested at the same concentration (10μM), so a comparison 
between their structure and activity could be established. Compounds 10; 22; 23 and 14; 17 
showed low solubility and were impossible to test at 10μM, being tested at 5μM or 1,5μM. 
At the same concentration, variations on cell viability between the compounds reflect the 
influence of the substituents. Therefore, high values of cell viability correspond to a weak 
effect and vice versa. Compounds that present more activity (values of cellular viability lower 
than about 40%) had their IC50 determined. All the results are summarized in the Table 2. 
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Compound 1-35 Compound 36 
 
Table 2 – Cellular viability of HCT116 (p53-wt) cells in the presence of the test compounds at 10μM and IC50 of the 
more active compounds. Values result from the mean ± SEM of at least three independent experiments. 
Compound R1 R 
Cellular viability 
(% at 10 μM) 
% Inhibition 
IC50 
(μM) 
1 
NH
NH
O Br
 
 
23 ± 4.3 77 ± 4.3 1.26 
2 
Cl
 
59 ± 4.7 41 ± 4.7 - 
3 
Cl
Cl
 
71 ± 3.5 29 ± 3.5 - 
4 
O
CF3
 
43 ± 3.7 57 ± 3.7 2.85 
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5 
CH3
Cl
 
56 ± 2.8 44 ± 2.8 - 
6 
OMe
 
70 ± 0.2 30 - 
7 
NH
O
NH
 
 
23 ± 3.9 77 ± 3.9 2.99 
8 
Cl
 
31 ± 3.9 69 ± 3.9 4.03 
9 
Cl
Cl
 
30 ± 4.9 70 ± 4.9 3.22 
10 * 
O
CF3
 
40 ± 5.3 60 ± 5.3 0.89 
11 
OMe
 
90 ± 7.7 10 ± 7.7 - 
12 
CH3
 
39 ± 1.9 61 ± 1.9 - 
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13 
OMe
 
39 ± 6.2 61 ± 6.2 - 
14** 
NH
NH
N
O
 
 
96 ± 3.5 4 ± 3.5 - 
15*** 
Cl
 - 
16*** 
Cl
Cl
 
17** 
O
CF3
 
78 ± 5.4 22 ± 5.4 - 
18 
NH
HN
O  
Cl
 
76 ± 1.4 24 ± 1.4 - 
19 
 
64 ± 2.9 36 ± 2.9 - 
20 
O
CF3
 
78 ± 6.2 22 ± 6.2 - 
21 
NH
NH
O
F 
 
38 ± 4 62 ± 4 2.72 
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22 * 
Cl
 
93 ± 5.9 7 ± 5.9 - 
23 * 
Cl
Cl
 
62 ± 1.8 38 ± 1.8 - 
24 
NH
NH
O
O
 
O
CF3
 
19 ± 3.8 81 ± 3.8 0.72 
25 
 
23 ± 1.6 77 ± 1.6 4.58 
26 
OMe
 
17 ± 3.6 83 ± 3.6 2.82 
27 
CH3
 
18 ± 2.3 82 ± 2.3 1.23 
28 
OMe
 
18 ± 2 82 ± 2 2.29 
29 
NH
NH
O
 
 
95 ± 0.5 5 ± 0.5 - 
30 
O
CF3
 
35 ± 4.4 65 ± 4.4 5.61 
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31 
NH
NH
O
 
 
65 ± 4.7 35 ± 4.7 - 
32 
NH
NH2 
O
CF3
 
44 ± 0.4 56 ± 0.4 - 
33 
 
35 ± 1.9 65 ± 1.9 7.94 
34 
NH
NH
O
S
 
OMe
 
38 ± 1.1 63 ± 1.1 - 
35 
N
 
OMe
 
93 ± 3.5 7 ± 3.5 - 
36 
HN
O
O
 
OMe
 
31 ± 1.4 69 ± 1.4 4.57 
In the table above are listed all the compounds tested and their effect on cellular viability at 10 μM. In a few cases, 
biological activity was measured at *5μM and **1.5μM due to low solubility. IC50 was calculated for the compounds that 
presented stronger inhibition (normally above 65%). *** These compounds were excluded due to their impossibility to 
dissolve, either in DMSO or water. 
 
 The results presented in Table 1 show that the biological activity of this new family of 
compounds depends on both substituents R and R1 present in the heterocyclic nucleus. 
Compounds having R=Ph and different R1 groups, 1, 7, 14, 19, 21, 25, 29, 31 and 33, show 23 
≤ % cellular viability ≤ 96. Compounds having R1=NHNHCO(3´-BrC6H4) and different R groups, 
1, 2, 3, 4, 5 and 6, show 23 ≤ % cellular viability ≤ 71. 
 Compounds 24, 25, 26, 27 and 28 having R1=NHNHCOfuryl and different aryl groups 
as R registered the highest activity (17 ≤ % cellular viability ≤ 23). For this set of compounds, 
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the R group does not seem to influence the activity. IC50 was then determined for these 
potent compounds and compound 24 emerged as the most active with an IC50 = 0.72 μM. 
High activity (23 ≤ % cellular viability ≤ 40) was also registered for compounds 7, 8, 9 and 10 
having the substituent R1=NHNHCOPh and different R groups. From these, the most active 
compounds, 7 and 10, were identified based on their IC50. Compound 7 showed IC50 = 2.99 
μM and compound 10 IC50 = 0.89 μM. However, compound 11, that also has R
1=NHNHCOPh 
but R=4-MeOC6H4, presents a very low activity (90 % of cellular viability). This result shows 
that the group R has a high influence on the activity.  
 The activity registered for compounds 1, 2, 3, 4, 5 and 6 having R1=NHNHCO(3´-
BrC6H4) and for compounds 21, 22 and 23 having R
1=NHNHCO(4´-FC6H4) varies a lot with the 
substituent R. While compound 1 shows a cellular viability of only 23%, compound 22 shows 
a cellular viability of 93%. 
 When compounds have the substituent R1=NHNHCOMe, NHNHCOEt or 
NHNHCO(CH2)6CH3 they show low activity (compounds 18, 19, 20, 29 and 31 have 64 ≤ % 
cellular viability ≤ 95) with the exception of compound 30 (cellular viability = 35%), which 
substituent R is the bulky group 4-CF3OC6H4. This set of results seems to suggest that a bulky 
alkyl group as substituent R1 is not favourable for activity, however, the presence of a bulky 
group in the substituent R is favourable. The activity registered for compounds 32 and 33 (% 
cellular viability = 44 and 35 respectively) and for compound 35 (% cellular viability = 93) also 
support the previous assumption. The group R1=NHNH2 is a very small group and both the 
compounds show high activity, yet the activity is very low when R1=piperidine, a very bulky 
group. 
 Compounds having R1=NHNHCO(4´-pyridine) showed low solubility either in DMSO or 
in water. It was only possible to prepare solutions of the compounds 14 and 17 at 300μM, 
being these compounds screened at the maximum concentration possible of 1.5μM (200-
fold lower than the stock). Compounds 15 and 16 were impossible to dissolve. Biological 
results showed that when R1=NHNHCO(4´-pyridine) compounds are less active. 
 The activity displayed by compound 28 (% cellular viability = 18) and by compound 36 
(% cellular viability = 31), whose structures differ only in the relative position of the R1 group, 
suggest that the position of R1 group in the heterocyclic nucleus also affects the activity of 
the compounds. 
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 From the SAR analysis of this family of compounds two hits emerged, compounds 10 
and 24 with IC50s of 0.89μM and 0.72μM, respectively. Both the compounds have R=4-
CF3OC6H4 but different R
1 substituents (R1=NHNHCOPh in compound 10 and NHNHCOfuryl in 
24). 
 
1.2. Activity of selected compounds in HCT116 (p53-null) and CO115 cells. 
 
 The two most potent compounds, i.e. with lower IC50s, tested on the HCT116 (p53-wt) 
cell line, compounds 10 and 24, were selected to proceed in this study (0.89μM and  0.72μM 
respectively). Compound 7 was also selected in order to compare the activity of the 2 
selected compounds with a compound that has simply phenyl groups as substituents R and 
R1, being for that reason denominated “naked” compound. Fluorouracil (5FU) is one of the 
most frequently used drugs on chemotherapy for the treatment of colon cancer31, reason 
why it was selected as a reference compound. The effect of p53 and KRas, frequently 
mutated genes in colon tumors26, on the activity of the compounds was assessed with the 
assistance of two additional cell lines, HCT116 (p53-null) with a complete knockout of p53 
and CO115 with an activating mutation on BRAF and KRas wildtype. 
 The results summarized in Table 3 show that the selected compounds are extremely 
active against all human colon cancer cells, in comparison with the reference drug 5FU. In 
the HCT116 (p53-wt) cell line, compounds 10 and 24 show a IC50 value (IC50= 0.89 and 
0.72μM) more than 15-fold smaller that the value of 5FU (IC50= 15μM). The dependency of 
the compounds’ effect on p53 was studied with HCT116 (p53-null) cells. The results clearly 
demonstrate that the effect of the compounds is independent of p53. This cell line, with a 
complete knockout of p53, is even more sensitive to the compounds than HCT116 (p53-wt). 
On the contrary, this cell line is resistant to 5FU, the reference compound. Since the 
mechanism of action of 5FU is dependent on p5333, it is expected that its effect on a cell line 
without p53 would be smaller, with a much higher IC50 (IC50=252.2μM). The “naked” 
compound presents a higher value of IC50 (IC50=2.24μM) than compounds 10 and 24, being 
still extremely potent.  
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Table 3 – IC50 of selected compounds and 5-FU in HCT116 (p53-wt), HCT116 (p53-null) and CO115 cell lines. 
   IC50 (μM) 
Compound R1 R 
HCT116 
(p53-wt) 
HCT116 
(p53-null) 
CO115 
10* 
 
NH
O
 
 
O
CF3
 
0.89 0.59 - 
24 
 
NH
O
O
 
 
O
CF3
 
0.72 0.55 1.55 
7 
 
NH
O
 
 
 
2.99 2.24 3.6 
5FU   15 252.2 29.5 
*Compound 10 was tested at 5μM, maximum concentration able to test with it. IC50 of this compound was 
impossible to calculate in CO115 cell line since 50% of cellular viability couldn’t be reached at this concentration. 
 
 With the CO115 cell line, the effect of the presence of normal RAS and a activating 
mutation on BRAF was analyzed. In this cell line, the IC50 of compound 10 was impossible to 
calculate, since 50% of cellular viability could not be reached at the maximum concentration. 
This result is particularly relevant since it allow us to imply that compound 10 may target 
mutant KRAS, only upstream component of BRAF in the MAPK/ERK pathway. This compound 
is extremely potent in both HCT116 cell lines, that harbour a mutation on KRAS. However, 
compound’s 10 effect on CO115 cell line, that has a activating mutation in BRAF instead of 
KRAS, decreases greatly, being even impossible to calculate its  IC50. Recalling the MAPK/ERK 
pathway (Figure 8), HCT116 cells mutation is situated in the beginning of the pathway, so the 
targeting of any of its components results in a decrease of proliferation. On the other hand, 
CO115 activating mutation on BRAF is more downstream on the pathway and the targeting 
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of any component upstream will not provoke any effect. CO115 showed to be slightly more 
resistant to the compounds effect than the previous two cell line. The IC50 of compounds 24 
and 7 increased to 1.55 and 3.6μM respectively, whereas 5FU shows an IC50 = 29.5μM, which 
is about 30 fold less active than the selected compounds. 
 In conclusion, the selected compounds 10, 24 and 7 are extremely potent in the three 
cell lines: HT116 (p53-wt), HCT116 (p53-null) and CO115, with the exception of compound 
10 in CO115. In addition, these compounds showed extremely high activity in HCT116 (p53-
null) cells, unlike 5FU (Fig.13), demonstrating that they are also active in tumours with this 
genetic profile, which can be an advantage in patient treatment, since patients with mutant 
p53 tumours are more resistant to the available treatment. 
 
H
N
HN
O
O
F
 
Figure 13 – Chemical structure of Fluorouracil (5-FU). 
 
1.3. Cellular Morphology 
 
 The morphology of HCT116 (p53-wt) cells was analyzed after incubation with the 
selected compounds for 48 hours (Fig.14). 
 
  
a) b) 
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Figure 14 – Cellular Morphology of HCT116 (p53-wt) cell line. Images above were obtained with an Olympus IX71 
inverted microscope and 10x1.6x objective lens in phase contrast mode after incubation with 5μM of compound 7 (b), 
5μM of compound 10 (c) and 10μM of compound 24 (d). Image a) is the control. 
 
 Cells were incubated with 5μM of compound 7 (Fig.14b), 5μM of compound 10 
(Fig.14c) and 10μM of compound 24 (Fig.14d). Relatively to control (Fig.14a) without the 
addition of any compound, it is visible an increase of dead cells (round and floating cells) 
with the selected compounds, particularly with the “naked” compound, i.e. compound 7. 
Incubation with compound 24 exhibits a higher amount of dead cells what may be due to 
the fact that it was tested at a higher concentration. In fact, through the analysis of the 
incubation with 5μM of compound 24 (result not presented) fewer less dead cells were 
visible than with compound 7, making compound 7 the better compound in death induction 
in this cell line. 
 A significant decrease in cell proliferation was produced by all compounds since the 
amount of cells attached to the bottom of the well decreases in comparison with control. 
Viable cells are attached to the bottom of the well and when they lose this attachment and, 
consequently, their shape, cells are no longer able to grow and proliferate. 
 
2. Compounds’ effect on apoptosis 
  
 With the goal of examining the effect of the best compounds on the induction of 
apoptosis, the nuclear condensation assay was performed. Compounds 10, 24 and 7 were 
incubated with the three cell lines for 48h and at various concentrations, as well as 5FU. 
c) d) 
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Statistical analysis was impossible to execute on CO115 cell line once data is the result of 
only two independent experiments. Results are presented in Figure 15. 
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Figure 15 – Effect of the selected compounds and 5-FU on apoptosis, assessed by the Nuclear Condensation assay. 
Apoptosis was evaluated after treatment with the compounds for 48h in the three cell lines. Values are mean ± SEM of at 
least 3 independent experiments, with the exception of CO115 cell line which only has 2. * P ≤0.05, ** P ≤ 0.01 and *** P ≤ 
0.001 in comparison with the control. 
 
 Observing the effect of the selected compounds on HCT116 (p53-wt) cell line, small 
increases in apoptosis are visible, in comparison with 5FU. The induction of apoptosis by 
compound 10 in this cell line is minimal and not significant, which indicates that the high 
activity of this compound is not due to the activation of this cell death mechanism. For 
compound 7, a relationship between its concentration and the apoptosis’ values can be 
established. At 1μM, neither compound 7 or 24 exhibit significant values of apoptosis. 
Increasing their concentration results in a higher induction of apoptosis, which values 
become significant. Examining the effect of 5FU, a directly proportional relationship 
between its concentration and the values of apoptosis is clearly visible. Even at 
concentrations much smaller than its IC50, 5FU shows a very high increase of apoptosis. This 
corroborates the research made about this compound, which revealed that 5FU mechanism 
of action leads to the activation of cells’ apoptotic pathways33. 
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 The effect of the compounds was then analyzed in the absence of p53 gene. To do so, 
compounds were incubated with HCT116 (p53-null) cell line that has a complete knockout of 
this gene. The most visible difference between effects with this cell line and the previous is 
for 5FU. An abrupt decrease on the effect of this compound was observed with HCT116 
(p53-null) cells, making p53 of extreme importance for 5FU mechanism of action47. This is 
also in agreement with previous studies about this compound, where low apoptosis was 
associated with the absence of p53, relatively to HCT116 (p53-wt)33;48;47 and patients’ cells 
without p53 show resistance to 5FU49. Focusing on the selected compounds, no significant 
differences occur in comparison with the effect in the previous cell line. This leads to the 
conclusion that the effect of the compounds 10, 24 and 7 does not depend on p53. In 
addition, no relationship between concentration and effect is established with these 
compounds. Furthermore, apoptosis is higher on the selected compounds than on 5FU, 
making them more active on this cell line. 
 The last cell line to be analyzed was CO115. This cell line was used in order to 
ascertain the effect of the compounds on apoptosis in the presence of mutated KRas gene 
versus BRaf. In this cell line, 5FU regains it activity due to the presence of p53, provoking the 
higher value of apoptosis from all the tested compounds. Relatively to the test compounds, 
there is a slight increase in apoptosis in comparison to the previous cell lines, making CO115 
more susceptible to the apoptotic effect of the compounds. From these, compound 24 
shows the higher increase in apoptosis’ values, which are proportional to concentration. 
 Through the analysis of the data gathered until this point, it is perceptible that 
apoptosis is not the cause of the extremely high activity of compounds 10, 24 and 7, once its 
low levels of apoptosis can not justify their activity. Although compounds are much more 
active than 5FU, the apoptosis’ induction rate of this approved drug is much higher, 
suggesting that these compounds act through different mechanisms of action. Another 
difference between 5FU and compounds 10, 24 and 7 is the dependence on p53 gene. While 
the effect of 5FU is completely dependent on the presence of this gene, the apoptosis levels 
of the selected compounds almost did not vary in the absence of p53. The results obtained 
with 5FU are consistent with literature50. Finally, in CO115 cells with constitutively active 
RAF apoptosis increases slightly for all the compounds. 
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3. Effect of the compounds on cell cycle 
 
 The necessity to study the cell cycle came from the need to understand the 
compounds’ mechanisms of action after discovering their poor induction of apoptosis. Once 
again, all the compounds, including 5FU, were incubated for 48h with the three cell lines and 
effects analyzed by flow cytometry. Results represent at least 3 independent experiments  in 
HCT116 (p53-wt). On the other two cell lines results were obtained with less than three 
independent experiments. Below are exposed representative images of the progression of 
the cell cycle in the three cell lines and in the presence of all the compounds. 
 
Control 
HCT116 (p53-wt) HCT116 (p53-null) CO115 
   
Figure 16 – Normal progression of cell cycle in the 3 cell lines. In the figure above is represented the distribution of single 
cells through the different phases of cell cycle, namely, G1, S and G2/M. Images are representatives from at least 3 
experiments in HCT116 (p53-wt) and  2 experiments for the other two cell lines. 
 
 The three images above represent the normal distribution of cells through the 
different phases of the cell cycle. The three cell lines were analyzed in the same conditions. 
Data is shown as number of cells (count) vs fluorescence intensity, which is proportional to 
DNA content. The first and second peaks represent the G1 and G2+M phases of the cell 
cycle, where cells have a DNA content of 2n and 4n7, respectively. The majority of the 
detected cells are in G1 phase, being followed from afar by cells on G2/M phase. The sub-G1 
phase is found before the G1 peak and, as expected in this state of equilibrium, the sub-G1 
value is close to the baseline. Logically, the S phase is located between the G1 and G2 
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phases, being its value concordant to the expected, on the three cell lines. DNA synthesis on 
the S phase is a rapid process, resulting in the small number of cells found in this phase7. 
 
Compound 10 
HCT116 (p53-wt) HCT116 (p53-null) CO115 
   
  
 
Figure 17 – Effects of compound 10 in cell cycle progression of the 3 cell lines. Assessment by flow cytometry was done 
after 48h of treatment. In the figure above is represented the distribution of single cells through the phases of cell cycle, 
namely, G1, S and G2/M. Images are representatives from at least 3 experiments in HCT116 (p53-wt) and  less than 3 
experiments for the other two cell lines. 
 
 The effect of the compound 10 on the progression of the cell cycle is represented 
above. Starting with the analysis of the main cell line of this project – HCT116 (p53-wt) – it is 
visible a very significant accumulation of cells on the G2/M phase, whose increase is 
proportional to the compound’s concentration. Comparing the results of this cell line with 
the ones of HCT116 (p53-null), a even more prominent S and G2 arrest is visible. This is in 
agreement with the activity results, where compound 10 showed to be slightly more active 
in this cell line without p53. Finally, observing the results of CO115, it is clear that there is 
the highest S arrest and smallest G2 arrest in comparison with the results of the previous cell 
lines. This accumulation of cells in the S phase is near the G1/S transition in comparison with 
the other cell lines, where the S arrest is closer to the G2/M peak. The accumulation of cells 
in the sub-G1 phase is also slightly bigger in this cell line. 
Results  and Discussion 
66 
 
 
Compound 24 
HCT116 (p53-wt) HCT116 (p53-null) CO115 
   
  
 
 
  
Figure 18 – Effects of compound 24 in cell cycle progression of the 3 cell lines. Assessment by flow cytometry was done 
after 48h of treatment. In the figure above is represented the distribution of single cells through the phases of cell cycle, 
namely, G1, S and G2/M. Images are representatives from at least 3 experiments in HCT116 (p53-wt) and less than 3 
experiments for the other two cell lines. 
 
 The images above represent the effect of compound 24 over the progression of the 
cell cycle. Starting again with the HCT116 (p53-wt) cell line, an extremely high G2 arrest was 
observed even in the lowest concentration, 0.5μM. With the increase of concentration, the 
G2 peak remains about half of the G1 peak, but a substantial accumulation of cells on the S 
phase is evident. The sub-G1 phase increase is also directly proportional to the compound’s 
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concentration. Analyzing now the HCT116 cell line with p53 knockout, a high S and G2/M 
arrest was observed. The increase of concentration provokes an abrupt augmentation on the 
levels of the S and G2/M phases. In comparison with the previous cell line at 5μM, these 
arrests are much higher, which is concordant with the IC50 results. Compound 24 showed 
more activity in HCT116 (p53-null) cells than on (p53-wt). Focusing now on CO115, more 
than the G2 arrest, a high S arrest is visible. In addition, there is also an accumulation of cells 
on the sub-G1 phase. 
 
Compound 7 
HCT116 (p53-wt) HCT116 (p53-null) CO115 
   
   
Figure 19 – Effects of compound 7 in cell cycle progression of the 3 cell lines. Assessment by flow cytometry was done 
after 48h of treatment. In the figure above is represented the distribution of single cells through the phases of cell cycle, 
namely, G1, S and G2/M. Images are representatives from at least 3 experiments in HCT116 (p53-wt) and  less than 3 
experiments for the other two cell lines. 
 
 Relatively to HCT116 (p53-wt) cells, a high accumulation of cells is observed in the 
G2/M phase with the presence of the compound 7. Contrary to the previous compound, 
there is not a noticeable increase in the S phase but a slight increase of cells in the sub-G1 
phase is visible. In both HCT116 (p53-null) and CO115 cell lines at 2.5μM, the G2 phase 
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suffered an extremely high arrest, being the G2+M peak at the same level of the G1. The 
increase of concentration in both cell lines, lead to a slight decrease of the G1 and G2+M 
peaks and an increase of S phase cells. In all the examples the accumulation of cells in the 
sub-G1 phase is bigger than with the previous compounds. This corroborates the previous 
morphological observations, where more cell death was detected with this compound. 
 
5FU 
HCT116 (p53-wt) HCT116 (p53-null) CO115 
 
  
   
 
  
Figure 20 – Effects of 5-FU in cell cycle progression of the 3 cell lines. Assessment by flow cytometry was done after 48h of 
treatment. In the figure above is represented the distribution of single cells through the phases of cell cycle, namely, G1, S 
and G2/M. Images are representatives from at least 3 experiments in HCT116 (p53-wt) and  less than 3 experiments for the 
other two cell lines. 
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 Progression of cell cycle was also studied with 5FU in the three cell lines. Starting the 
analysis with HCT116 (p53-wt) cell line as usual, almost no disturbance was observed at 
0.5μM, the lowest concentration, in comparison with control. Only the sub-G1 phase 
increased slightly. Taking into account that the IC50 of 5FU is 15μM in this cell line, this 
dosage is extremely low to provoke any significant effect. The increase of concentration is 
accompanied by a consequent increase in cells on the G2 and sub-G1 phases. 
 Cell cycle progression in HCT116 (p53-null) cells at 15μM was altered in comparison 
with HCT116 (p53-wt), in consequence of the p53 gene knockout. A high G2 arrest was also 
observed with these cells, accompanied by a higher accumulation of cells in the S phase but,  
contrary to the previous cell line, the cell cycle of HCT116 (p53-null) cells lacks the increase 
of sub-G1 phase observed with HCT116 (p53-wt), as reported in a previous work33. Once the 
sub-G1 fraction is an indication of DNA fragmentation7, typical of apoptosis, nuclear 
condensation results are concordant with this observation. The nuclear condensation assay 
clearly revealed the dependence of 5FU’s induction of apoptosis on p53 wt presence. 
 The incubation of CO115 cells with 5FU at 15μM was ineffective in the disturbance of 
the cell cycle. Both sub-G1 and G2 phases, typically arrested with this reference drug, did not 
present any significant accumulation of cells. Only S phase suffered a slight arrest in 
comparison with control and prior cell lines. 
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Figure 21 – Effect of the compounds in cell cycle (a) and in the percentage of cells at sub-G1 fraction (b) in HCT116 (p53-
wt). Values are mean ± SEM of 3 independent experiments. * P ≤0.05, ** P ≤ 0.01 and *** P ≤ =0.001 in comparison with 
the control. 
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 Data from at least three independent experiments of all the compounds tested in 
HCT116 (p53-wt) cells was treated statistically and presented in Figure 21a. Relatively to the 
cell cycle analysis on the left, all the compounds presented a lower G1 peak and higher S and 
G2/M phase arrest relatively to control, with the exception of compound 7 at 1μM. At its 
lowest concentration, 1μM, compound 7 does not provoke any significant variation in the 
progression of the cell cycle. The increase of compound 7 concentration causes the 
accumulation of cells in the S and G2/M phase and, consequently, the decline of cells in G1 
phase. Compound 10 shows a significant G2 arrest on concentrations superior to 0.5μM. This 
concentration independent variation of the G2+M peak is accompanied by the decrease of 
the G1 peak. S phase remained constant at different concentrations with this compound. A 
more pronounced S phase arrest was seen with compound 24. At its lowest concentration, 
0.5 μM, compound 24 presents a very high G2 arrest, which diminishes with the increase of 
concentration. Concomitantly, cells rapidly accumulate in the S phase, resulting in the 
extremely high arrest observed at 10μM. Knowing this, it can be assumed that this 
compound interferes with the synthesis of DNA in the S phase, maybe by introducing errors 
in the DNA chain, recognized by the cell and that ultimately lead to the arrest of the cell 
cycle. In general, these three compounds cause the arrest of the S and G2/M phases in 
HCT116 (p53-wt) cells. The effect of the reference compound 5FU in the progression of the 
cell cycle was also analyzed. As represented above, 5FU also caused the arrest of the cell 
cycle in the G2/M phase. Only at 10μM this augmentation of cells in G2/M phase is 
significant. This result is concordant with a previous study where 5FU was related with G2/M 
arrest in HCT116 (p53-wt) cells33. 
 The effect of the compounds on the sub-G1 phase of HCT116 (p53-wt) cells was also 
analyzed (Fig.21b). The sub-G1 fraction of the cell cycle, whose DNA content is lower than 
2n, is representative of DNA fragmentation, typical of apoptosis. Through the observation of 
Fig.21b it is clear that the selected compounds do not cause any significant effect on the 
apoptotic levels of these cells, with the exception of compound 7 at 10μM. These results 
corroborate the nuclear condensation analysis, where low values of apoptosis were 
detected, with the same incubation parameters. From the three, only compound 7 reveals a 
concentration dependent effect, as observed with the nuclear condensation assay. As 
expected due to the previous analysis and reported works33, 5FU caused a high 
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accumulation  of cells in the sub-G1 phase, in concentrations much lower than its IC50. This 
concentration dependent effect is also concordant with the nuclear condensation results. 
 Insufficient data did not allow the statistical analysis of cell cycle progression in the 
other cell lines. 
 
 Analyses made so far lead us to the conclusion that our test compounds and 5FU 
function through different mechanisms of action. While apoptosis cannot be taken as the 
main target of our selected compounds, 5FU clearly functions through its induction. On the 
other hand, it was proved that the selected compounds’ mechanism of action interferes 
directly with the progression of the cell cycle, causing a higher arrest of the S and G2/M 
phases than 5FU. 
 
  
4. Effects on molecular targets of proliferation and death 
 
  After the discovery of the compounds’ main effect, the arrest of the cell cycle, levels 
of several molecular targets were analyzed by western blot with the goal of enlightening the 
compounds’ mechanism of action in HCT116 (p53-wt) cells. This was achieved by the 
identification of the compounds effect on the expression of various proteins with some 
initial experiments of Western blot. In Figure 22 are represented the effects of compounds 
10 (Fig.22a) and 24 (Fig. 22b), the most potent, in the expression of various proteins related 
with cell cycle and death. 
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Figure 22 – Effect of compounds 10 (a) and 24 (b) on the expression of several markers involved in cell cycle and death in 
HCT116 (p53-wt) cells. Results were obtained by Western Blot. Β-actin was used as a loading control. Images are 
representative of 3 independent experiments. 
 
  The phosphorylation of ERK, indicative of the activation of the MAPK/ERK pathway, 
was tested in order to assess the effect of the compounds in this pathway. The importance 
of MAPK/ERK comes from the fact that this pathway is activated in a high number of CRC 
cases, resulting in increased proliferation and inhibition of apoptosis51. As presented in 
Fig.22a, compound 10 decreases phosphorylation of this protein, what suggests a decrease 
in proliferation levels30. In addition to this signaling pathway involved in the control of 
proliferation and induction of apoptosis, two other stress-activated pathways with the same 
function of control were studied, namely the JNK and p38 pathways52. Both compounds 10 
and 24 cause an increase in the levels of both pJNK and p-p38, particularly the last one. 
Compound 24 presents a higher expression of both proteins in comparison with compound 
10, what indicates a higher induction of apoptosis30. This inference is concordant to the 
previous nuclear condensation analysis, where compound 24 showed a higher induction of 
apoptosis than compound 10. The expression of p-p38 in the presence of compound 10 also 
shows a concentration dependent effect. The expression of the apoptotic marker PARP-1 
was also tested in order to assess the induction of apoptosis and its dependency on caspase 
activation. In the event of caspase mediated apoptosis, PARP-1 is cleaved by caspases and, 
consequently, inactivated which is associated with increased apoptosis 53. Both compounds 
presented a slight increase of cleaved PARP-1 expression. The low levels of cleaved PARP 
shown, can be explained by the very small induction of apoptosis by the compounds, as 
a) b) 
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demonstrated with the previous results. Reminiscing of the cell cycle analysis, where a high 
G2/M arrest was identified, molecular markers related with the cell cycle progression were 
also tested, namely Cdc25c and p53. Cdc25c phosphatase activates the cdk1/cyclin B 
complex inducing, consequently, the transition from the G2 to the M phase12 (Fig.4). In the 
presence of the 3 test compounds and 5FU (Figures 22 and 23), it is visible a high decrease in 
the expression of this phosphatase, what supports the cytometry results. Other result 
concordant to the G2/M arrest is the increased expression of the p53 protein in the 
presence of compounds 24 and 10. p53 regulates the synthesis of many proteins involved in 
several stress activated responses like, for example, apoptosis and cell cycle arrest. 
Depending on cell type and stimulus, the p53 post-transcriptional network can be modified, 
leading to an increase of apoptosis levels and/or arrest of cell cycle54. Given the low values 
of apoptosis obtained with these compounds, it is expected that the high increase of p53 
expression is related with the S and G2/M cell cycle arrest observed, possibly by induction of 
the synthesis of inhibitors of the cdk1/cyclin B complex, like p21, Gad45 and 14-3-32,54 
(Fig.4). 
 
  
Figure 23 - Effect of compound 7 (a) and 5FU (b) on the expression of several markers involved in cell cycle and death in 
HCT116 (p53-wt) cells. Results were obtained by Western Blot. Β-actin was used as a loading control. Images are 
representative of 3 independent experiments. 
 
 The effect of compound 7 (Fig.23a) and the reference compound 5FU (Fig.23b) in the 
expression of various proteins related with the cell cycle and death was also investigated. 
With compound 7 is visible a clear concentration dependent increase of the PARP cleavage, 
another apoptotic marker. The higher levels of cleaved PARP expression of compound 7 in 
comparison with 24 and 10 agree with to the higher induction of apoptosis by this 
compound. This induction of apoptosis by compound 7 does not seem to be JNK dependent. 
As with the preceding compounds, it is visible an abrupt decrease in Cdc25c expression and a 
a) b) 
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increase of p53, suggesting that this compound also acts on the cell cycle progression. 5FU 
presents a similar protein expression but, in light of the previous results, it needs to be 
interpreted in a different way. The reduction of cdc25c and increased p53 expression may be 
related with the cell cycle arrest in G2/M but, given the slightly lower arrest and much higher 
values of apoptosis that 5FU presents in comparison with the tested compounds, seems to 
indicate that p53 induction by 5FU leads to the induction of apoptosis. Previous studies have 
reported increased p53 expression after treatment with 5FU55. Concerning the expression of 
other apoptotic markers, a slight increase in the levels of p-p38 and cleaved PARP is visible. 
The small increase in the expression of these proteins can be a consequence of the small 
induction of apoptosis due to the low concentration at test (5μM) relatively to 5FU’s IC50 in 
this cell line (15μM). 
 
 Other molecular markers, mostly related with the cell cycle progression, need to be 
analyzed, as well as a more extensive study of the expression of these proteins, in order to 
take more accurate conclusions. 
 
5. Fluorescence 
 
 In the initial investigation, compound 2 has show fluorescence with a FITC filter46, as 
demonstrated in Fig.24. This property was also investigated for the selected compounds but 
none of them showed fluorescence (data not presented). 
  
Figure 24 – Fluorescence assessed in HCT116 (p53-wt) cells in the absence (a) and presence of the previously studied 
compound 2 (b). Images above were obtained with an Olympus IX71 inverted microscope and 10x objective lens with FITC 
filter. 
 
a) b) 
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6. DNA damage and Senescence 
 
 The effect of the selected compounds on senescence and DNA damage was evaluated with a 
single preliminary experience in HCT116 (p53-wt) cells. Compounds were tested at different 
concentrations but results were inconclusive.  
 
 
 
 With this project a new and promising family of compounds was discovered. Starting 
with an initial structure, several substitutions were made in the R and R1 groups. Both groups 
interfere with the activity of the compounds and some were identified as especially 
important for their activity, namely phenyl and furan for R1 and phenyl and OCF3 for R. From 
this group, 2 compounds (10 and 24) were identified as extremely potent and promising in 
comparison with the reference drug 5FU. These compounds were also tested in cell lines 
with a complete knockout of p53 (HCT116 (p53-null)) and with an activating mutation in the 
BRaf gene instead of KRas (CO115). Compounds 10 and 24 show independency of the p53 
status, what confers an advantage relatively to 5FU in the treatment of CRC which is 
completely dependent on the presence of functional p53. Compound 24 was also active in 
cells with mutated BRaf but compound 10 lost all of its activity what indicates that this 
compound may target KRas. 
 The effect of the best compounds was tested in the induction of apoptosis in the 3 
cell lines. The induction of apoptosis by these compounds was low in all cell lines and, once 
again, the independency of p53 was established. On the other hand, 5FU demonstrated 
again its dependency. In the presence of p53, 5FU caused a high induction of apoptosis but 
in its absence 5FU had no effect. Given the high activity of the compounds and their low 
induction of apoptosis, it can be assumed that their main mechanism of action does not 
induce apoptosis. These results were corroborated by the cell cycle analysis where the arrest 
of the sub-G1 phase in HCT116 (p53-wt) cells, indicative of apoptosis, was very low. 
Contrary, the arrest of the S and G2 phases was extremely high in this cell line with 
compounds 10 and 24. This effect may be due to the inhibition of cyclin B, regulator of the 
G2 transition, by the compounds. Although our compounds are not similar to any known 
inhibitor of the G2 transition, they may target the complex cyclin B/Cdk1 or any of its 
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regulatory proteins. Knowing that the high S and G2 arrest still happens in the absence of 
p53, the p53 independent ATM/ATR pathway is an interesting target of study. Compounds 
10 and 24 may be interfering with components of this pathway like CHK1 and 2, for example, 
or even with the Ccd25 phosphatase. The expression of some molecular markers was 
studied with HCT116 (p53-wt) cells. The expression of cleaved PARP protein corroborated 
once again the low induction of apoptosis by our compounds. On the other hand, the 
expression of Cdc25c and p53 corroborated the cell cycle results, indicating a high G2 arrest. 
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1. Final Remarks 
 
 Throughout the course of this research, all aims set in the beginning were fulfilled 
with success. The biological activity of several nitrogen heterocycles belonging to the same 
family was evaluated by the MTT assay, in the HCT116 (p53-wt) cell line. With this study it 
was possible to conclude that both substituents R and R1 present in the heterocyclic nucleus 
of the compounds interfere with their activity. More than this, results seem to suggest that a 
bulky alkyl group as substituent R1 is not favourable for activity, however, the presence of a 
bulky group in the substituent R is. In this family of compounds two extremely active hits 
emerged, namely compounds 10 and 24, with IC50s of 0.89μM and 0.72μM, respectively. 
These compounds, in addition with the naked compound 7, were selected to continued in 
the study. 
 The biological activity of compounds 10 and 24 was tested in different cell lines with 
p53 knockout (isogenic HCT116 (p53-null)) and mutant BRAF (CO115), in order to assess if 
their activity if dependent on p53 and KRAS/BRAF status. Compounds proved to be very 
promising by their extremely high activity in the studied cell lines, relatively to a reference 
drug (5FU). Particularly in the absence of functional p53, a mutation related with resistance 
to anticancer drugs such as 5FU, test compounds were extremely active, what provides an 
advantage in the treatment of patients. In CO115 cells, with an activating mutation in BRAF 
gene, the IC50 of compound 10 was impossible to calculate since its activity was very low. 
This lead to the assumption that this compound may targets KRAS gene. 
 The effect of the test compounds was then assessed in the induction of apoptosis and 
progression of the cell cycle. Relatively to the induction of apoptosis, the selected 
compounds presented a low effect, with no dependency in the p53 status. Contrary, 5FU 
presented a high induction of apoptosis in the presence of active p53 but almost no effect in 
its absence. The results obtained for the induction of apoptosis are concordant with the cell 
cycle analysis. The three compounds showed a low arrest of cells at sub-G1 phase, 
representative of apoptosis, in comparison with 5FU in HCT116 (p53-wt) cells. Relatively to 
the progression of the cell cycle in HCT116 (p53-wt) cell line, compounds 10 and 24 cause a 
accentuated arrest of cells in the G2/M and S phases, respectively. Given the very high S 
arrest provoked by compound 24 it is thought that this compound interferes with the DNA 
synthesis. 5FU also provokes a cell cycle arrest at G2/M phase. These results clearly indicate 
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that the test compounds and the reference compound, 5FU, have very distinct effects. While 
the most evident effect of 5FU is on the induction of apoptosis, our compounds are more 
efficient in the arrest of the cell cycle at S and G2/M phases. The initial analysis of molecular 
markers related with cell death and proliferation in HCT116 (p53-wt) cells sustains the 
previous conclusions. In addition, compounds 10 and 24 did not presented fluorescent with 
a FITC filter. 
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2. Future Perspectives 
 
 The work developed so far with this family of compounds paved the way for many 
lines of work in the future. Relatively to the work already performed, it would be beneficial 
to conclude the statistical analysis of the flow cytometry analysis in the HCT116 (p53-null) 
and CO115 cell lines. It would be also interesting to study possible targets, by the test of new 
molecular markers related with cell cycle arrest at S and G2 phase, like for example Chk1, 
topoisomerase and Cdc25A56, as well as a statistical analysis of the markers already tested in 
the three cell lines. In the same way, the preliminary studies of senescence and DNA damage 
could be developed with the β-galactosidase and comet assay, respectively. 
 The study of the mechanism of action of the two hit compounds, 10 and 24, can also 
be deepened. In order to do so, the possibility of compound 10 to target KRAS protein can 
be ascertain, for example, by the expression of KRAS and downstream proteins in HCT116 
and CO115 cell lines or in cell lines with a KRas knockout. Relatively to compound 24, that 
causes a strong S phase arrest, it would be relevant to compare this arrest with a reference 
compound that also causes S phase arrest like Roscovitine or even 5FU, for example. 
 Knowing that the absence of a functional MMR system is related with drug 
resistance57 and that compounds 10 and 24 were very active in MMR-deficient cell lines, it 
will be important to assess the effect of the compounds in a cell line with functional MMR, 
like Caco-2 for example. This cell line is able to detect certain DNA damages due to the 
presence of functional MMR system, that translate them into DNA breaks, visible through 
the COMET assay. HCT116 cells do not detect these damages and, in consequence, no 
comets appear. In this project, the independency of the compounds’ effect in the presence 
of p53 was established with cell lines with and without p53. In the future it would also be 
interesting to study the effect of compounds 10 and 24 in cells with mutated p53 like, for 
example, HCT15 cells. 
 Although the focus of this project Is the treatment of colon cancer it would also be 
interesting to assess the effect of our compounds in other types of cancer like breast cancer. 
An important characteristic to have into account is the compounds’ specificity to cancer 
cells. This can be determined by the analysis of the compounds’ effects on “normal” cells, 
namely ASF-2 fibroblasts. Synergy studies with the selected compounds and reference drugs, 
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like 5FU and cisplatin for example, can be made in the hope of maximizing their anticancer 
activity.  
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